

CURRICULUM VITAE: DAVID J. WAXMAN

ADDRESS: Department of Biology, Boston University
5 Cummington Street
Boston, MA 02215
Telephone: (617) 353-7401; Fax: (617) 353-7404; Email: djw@bu.edu

EDUCATION:

1972-1975 B.A. in CHEMISTRY, Queens College, CUNY
1975-1976 A.M. in CHEMISTRY, Harvard University
1976-1980 Ph.D. in BIOCHEMISTRY and MOLECULAR BIOLOGY, Harvard University

POSTDOCTORAL TRAINING:

1980-1983 Research Fellow, Department of Chemistry, Massachusetts Institute of Technology

ACADEMIC APPOINTMENTS:

1983-1986 Assistant Professor of Biological Chemistry,
Department of Biological Chemistry and
Dana-Farber Cancer Institute, Harvard Medical School
1986-1993 Associate Professor of Biological Chemistry (1986-1987) and of
Biological Chemistry & Molecular Pharmacology (1987-1993),
Department of Biological Chemistry & Molecular Pharmacology and
Dana-Farber Cancer Institute, Harvard Medical School
1994-present Professor of Cell and Molecular Biology, Department of Biology, Boston University
1998-present Professor of Medicine, Boston University School of Medicine

AWARDS, HONORS and SPECIAL APPOINTMENTS:

1972-1975 New York State Regents Scholar
1975 Konkol Chemistry Prize, Queens College, CUNY
1975 Summa Cum Laude, Queens College, CUNY
1975 Phi Beta Kappa
1980 Jane Coffin Childs Fund for Medical Research Fellowship (*declined*)
1980 Anna Fuller Fund Fellowship (*declined*)
1980 Visiting Scientist, Department of Biophysics, Weizmann Institute of Science
1980-1981 Damon Runyon-Walter Winchell Cancer Fund Fellowship
1981-1983 National Institutes of Health Postdoctoral Fellowship
1983 Research Corporation Award
1988 Rita Allen Foundation Scholar Award, Harvard Medical School nominee, Awardee finalist
1993 Burroughs-Wellcome Endocrine Toxicology Symposium Lectureship
1994-1998 Howard Hughes Medical Institute-sponsored Senior Faculty Appointment, Boston Univ.
1999-2005 Deputy Director, Superfund Basic Research Program, Boston University
2000-2001 Visiting Scientist, Cancer Genomics Program, Whitehead Institute Genome Center, M.I.T.
2003-present Top 100 Cited Researchers in Pharmacology and Toxicology, Thomson-ISI
Citation rank: 13 of top 100 researchers for 1996-2006
2005 Twenty Year Highly Cited Researcher in Pharmacology, 1985-2004, Thomson-ISI

EDITORIAL BOARD MEMBERSHIPS:

1990-1994 Associate Managing Editor, Biochimica et Biophysica Acta, Elsevier Science Publishing
1995-1997 Associate Executive Editor, Biochimica et Biophysica Acta, Elsevier Science Publishing
1992-present Editorial and Advisory Board, Molecular Pharmacology
1992-present Editorial Advisory Board, Biochemical Journal
1992-present Editorial Board, Pharmacology

1993-present	Editorial Academy, International Journal of Oncology
1994-present	Editorial Board, Drug Metabolism and Disposition
1996-2000	Editorial Board, Journal of Biological Chemistry
1997-present	Editorial Advisory Board, Journal of Pharmacy and Pharmaceutical Sciences
1997-present	Editorial Board, Xenobiotica
1997-present	Editorial Academy, International Journal of Molecular Medicine
1999-present	Editorial Board, Cancer Gene Therapy
2000-2003	Editorial Board, Molecular Endocrinology
2001-present	Editorial Board, Molecular Cancer Therapeutics
2002-2004	Editorial Advisory Board, Biochemical Pharmacology
2002-2005	Editorial Board, Endocrinology
2003-present	Editorial Board, Cancer Therapy
2004-present	Associate Editor, Letters in Drug Design and Discovery
2004-present	Editorial Board, Medical Hypothesis and Research
2004-2006	Editorial Board, Archives of Biochemistry and Biophysics
2005-present	Editorial Board, Medicinal Chemistry
2006-present	Associate Editor, PPAR Research
2006	Managing Editorial Board, Frontiers in Bioscience (<i>dedined</i>).
2007-present	Editorial Board, Open Drug Metabolism
2007	Editorial Advisory Board, Recent Patents on Endocrine, Metabolic and Immune Drug Discovery (<i>dedined</i>)
2007	Editorial Board, The Open Toxicology Journal
2008-2011	Editorial Board, Endocrinology

STUDY SECTION REVIEW PANEL ACTIVITIES:

1987	NIH Neurological Sciences Study Section (<i>Ad Hoc</i>)
1987-1989	NCI Carcinogenesis Study Section, Site Visit Committee (<i>Ad Hoc Member</i>)
1991-1994	NIH Physical Biochemistry Study Section (<i>Regular Member</i>)
1992	NIDDK Special Grants Study Section (<i>Ad Hoc</i>)
1994	NCI Program Project Site Visit Committee (<i>Member</i>)
1996	NIH Toxicology Study Section (<i>Ad Hoc</i>)
1997	NCI Intramural Review Board, Site Visit Committee (<i>Member</i>)
2001	NIEHS Special Emphasis Review Panel: Oxidative Stress (<i>Member</i>)
2003	NIH Alcohol and Toxicology Special Emphasis Review Panel (<i>Member</i>)

OTHER REVIEW PANEL and ADVISORY ACTIVITIES:

1983-1985	Research Consultant, Department of Chemotherapy, Hoffman-La Roche, Inc., NJ
1986-1987	Research Consultant, Division of Hepatic Diseases, NYU Medical Center, NY
1991-1992	Research Consultant, Dept. of Pathology, Rhode Island Hospital, Brown University
1990-1996	Committee on P450 Gene Superfamily Nomenclature
1990	Extramural Advisory Committee, Proposed NASA Specialized Center of Research and Training (NSCORT), Univ. of Louisville, School of Medicine.
1993	American Assoc. of Cancer Research, 1994 Annual Meeting Program Committee
1994	American Inst. Biological Sciences, U.S. Army Breast Cancer Research Program
1996-1998	International Advisory Committee, 12th Intl Symposium on Microsomes and Drug Oxidations (Montpellier, France)
1997	Intramural Review Board of Scientific Counselors, NIEHS, <i>Ad Hoc</i> member
1998-present	International Advisory Board, Microsomes and Drug Oxidations Meeting Series
1998	Scientific Advisory Committee, Brain Tumor Gene Therapy Program, Massachusetts General Hospital, Harvard Medical School
1998-1999	Scientific Advisory Committee, Environmental Health Science Center at Institute of Chemical Toxicology, Wayne State University
1998-present	Scientific Advisory Board, Oxford BioMedica, Oxford, United Kingdom
1998-2000	International Advisory Committee, 13th Intl Symposium on Microsomes and Drug Oxidations (Stresa, Italy)
1999-present	New England Drug Metabolism Discussion Group, Steering Committee and Founding Member

- 2000-present Chairman, Scientific Advisory Committee, Environmental Health Science Center
at Institute of Chemical Toxicology, Wayne State University
- 2001-present Endocrine Society, Annual Meeting Abstract Review Committee
- 2001-present Scientific Advisory Board, Metabasis Therapeutics, San Diego
- 2001-2002 University of Kansas, NIH COBRE Award Review Panel
- 2002-2004 International Advisory Committee, 15th Intl Symposium on Microsomes and Drug
Oxidations (Mainz, Germany)
- 2003 GH-IGF Int'l Symposium 2004, Abstract Review Committee
- 2007- External Examiner, PhD Thesis Defense, Karolinska Institute, Stockholm
- 2007-present University of Rhode Island, External Advisory Committee, NIH COBRE Award.

MAJOR RESEARCH INTERESTS:

Molecular Endocrinology and Cell Signaling, Cancer Gene Therapy, Nuclear Receptors in Toxicology,
Liver Gene Expression, Anticancer Pharmacology, Prodrug Activation, Drug Action and Drug
Resistance, Steroid Metabolism and Action, Biochemistry of Membrane Proteins

SPECIALIZED FIELDS of EXPERTISE

Growth Hormone signaling and liver gene expression
Sexual dimorphism of hepatic cytochrome P450
Regulation of liver P450s by nuclear receptors and xenobiotics
Prodrug-activation gene therapy for cancer
Hepatic drug metabolism and cancer pharmacology

UNIVERSITY and DEPARTMENTAL PROGRAMS and COMMITTEES:

- 1983-1985 Animal Care and Use Committee, Dana-Farber Cancer Institute
- 1983-1990 Program in Cell and Development Biology, Harvard Medical School
- 1984-1988 Program in Higher Degrees in Biophysics, Harvard University
- 1986-1987 Seminar Series Committee, Dept. of Biological Chemistry, Harvard Medical School
- 1986-1991 Seminar Series Committee, Dana-Farber Cancer Institute
- 1988-1991 Junior Faculty Search Committees, Toxicology Program, Harvard Sch. of Public Health
- 1995-1998 Cell and Molecular Biology Seminar series, Co-chair, Boston University
- 1996-1997 Dept. of Biology Graduate Committee, Boston University
- 1996-1997 Dept. of Biology Academic Conduct Committee, Boston University
- 1996-1997 Molecular Biology, Cellular Biology and Biochemistry Program,
Graduate Admissions Committee, Boston University
- 1996-1998 Dept. of Biology, Biochemistry Graduate Qualifying Exam Committee
- 1997-1998 Cell and Molecular Biology, Junior Faculty Search Committee, Boston University
- 1997-1999 Boston University Medical Center, Continuing Medical Education Faculty
- 1995-present Accelerated Medical Program Admissions Committee, Boston University
- 1996-present Turner Award Committee, Boston University
- 1997-2000 Institutional Animal Care and Use Committee, Boston University
- 1998-2000 Dept. of Biology Graduate Committee, Boston University
- 1998-1999 Graduate Committee on Academic Standards, Boston University
- 1998-2000 Dept. of Biology, Graduate Preliminary/Qualifying Examination Committee, Chairman
- 1999-2000 Bioinformatics Program Seminar Committee
- 1999-2000 Dept. of Biology, Library and On-line Journals Committee, Chairman
- 1999-2000 Cell and Molecular Biology, Junior Faculty Search Committee, Boston University
- 2001-2003 Graduate Program in Bioinformatics, Admissions Committee
- 2002-2004 Dept. of Biology, Appointments, Tenure and Promotion (APT) Committee
- 2004-2005 Graduate Program in Bioinformatics, Advising, Recruitment and Application Review
Committee, Boston University
- 2005-2006 Bioinformatics Program, Faculty Search Committee
- 2005-present Boston University Charles River Campus Patent Committee
- 2006 Dept. of Biology, Faculty Merit Review Committee
- 2006 Science and Engineering Research Symposium, Poster Judge Committee
- 2006 Faculty Facilitator, Responsible Conduct of Research Training Program

2006-2007 Dept. of Biology, Faculty Search Committee, Cell and Molecular Biology
 2006-2007 Chairman, Academic Standards Committee, Bioinformatics Program
 2007-2012 Bioinformatics NSF IGERT Training Grant, Co-PI

SOCIETY MEMBERSHIPS:

1986-present American Society for Biochemistry and Molecular Biology (ASBMB)
 1986-present American Association for Cancer Research (AACR)
 1988-present The Endocrine Society
 1992-present The Biochemical Society
 1993-1995 American Association for the Study of Liver Diseases (AASLD)
 1994-present International Society for the Study of Xenobiotics (ISSX)
 1997-present Canadian Society for Pharmaceutical Sciences (CSPS), Honorary Member
 1999-present American Society for Pharmacology and Experimental Therapeutics (ASPET)
 2002-present Growth Hormone Research Society (GRS)
 2002-present American Society for Gene Therapy

OTHER REVIEW ACTIVITIES:

JOURNAL REVIEW

Reviewer of Journal Articles for numerous Scientific Journals, including: Antimicrob Agents Chemother, Am J Human Genetics, Am J Physiol, Archives Biochemistry and Biophysics, BMC Molecular Biology, Biochem and Cell Biology, Biochem J, Biochemistry, Biochimica Biophysica Acta, Biochemical Pharmacology, Biology Reproduction, Br J Pharmacol, Can J Physiol Pharmacol, Cancer Chemother Pharmacol, Cancer Gene Therapy, Cancer Research, Cell Death and Differentiation, Chemical Research in Toxicology, Chirality, Clin Canc Res, Diabetes, Drug Metab Dispos, Endocrinology, Eur J Biochem, Eur J Clin Pharmacol, Eur J Pharmacol, FASEB J, Gastroenterology, Gene Therapy, Genetic Analysis, Genomics, Hepatology, Intl Immunol, Intl J Cancer, Intl J Oncology, J Am Geriatric Soc, J Acquired Immune Deficiency Syndromes, J Bacteriology, J Biochemical Toxicology, J Biological Chemistry, J Cell Biology, J Clinical Investigation, J Clinical Oncology, J Clinical Psychopharmacology, J Gene Medicine, J Infectious Diseases, J Inorganic Biochem, J Lipid Res, J Molec Endocrinol, J Molec Evolution, J Neuroendocrinology, J Pediatr Endocrinol Metab, J Pharm Exp Therap, Metabolism Clinical and Experimental, Molecular Cancer Therapeutics, Molecular Carcinogenesis, Molecular Cellular Biology, Molecular Endocrinology, Molecular Genetics and Metabolism, Molecular Pharmacology, Nature Biotechnology, Pediatric Endocrinol Reviews, Pediatric Research, Pharmacogenetics, Physiological Genomics, Proc Natl Acad Sci USA, Proc Soc Exp Biol Med, Protein Science, Science, Toxicology, Toxicol Appl Pharmacol, Trends in Genetics, Trends in Pharmacol Sciences, Xenobiotica

RESEARCH GRANT REVIEW

Reviewer of Research Grant Proposals and Foundation Awards for: National Institutes of Health, National Science Foundation, American Cancer Society, American Institute of Biological Sciences, Anti-Cancer Foundation of Univ S Australia, Assoc Francaise contre les Myopathies, Association for International Cancer Research, Australia Research Grants Science, Biotechnology and Biological Sciences Research Council – UK, British Columbia Health Care Research Foundation, Canadian Institutes of Health Research, Eppley Foundation, Hong Kong Research Grants Council, International Science Foundation, Israel Academy of Sciences and Humanities Basic Research Foundation, Josef Steiner Foundation Cancer Research Award, Louisiana Board of Regents Research Support Fund, Medical Research Council of Canada, Raine Medical Research Foundation, Research Corporation, Scotland Biomedical and Therapeutic Research Committee, Swiss National Science Foundation, Veterans Administration, Wellcome Trust

INVITED SPEAKER – NATIONAL and INTERNATIONAL CONFERENCES and MAJOR SYMPOSIA:

Table Ronde Roussel Uclaf on β -Lactam Antibiotics
 Paris, France, December 1979.
 EMBO Workshop on Mode of Action of β -Lactam Antibiotics
 El Escorial, Spain, July 1982.

- Janssen Research Foundation 4th International Symposium on Comparative Biochemistry: Cytochrome P-450. Beerse, Belgium, August 1985.
- Cytochrome P-450 - 25 Years of Progress
Philadelphia, Pennsylvania, June 1987.
- 3d Biochemical Pharmacology Symposium: Stereochemistry in Drug Action
Oxford, United Kingdom, July 1987.
- Gordon Research Conference on Hormonal Carcinogenesis
New Hampton, New Hampshire, August 1987.
- Mannerling Symposium on Drug Metabolism
Minneapolis, Minnesota, June 1988.
- 6th International Conference on Biochemistry and Biophysics of Cytochrome P450
Vienna, Austria, July 1988.
- U.S.-Japan Cancer Cooperative Meeting: Cytochrome P450 and Carcinogenesis
Oahu, Hawaii, January 1989.
- 8th International Symposium on Microsomes and Drug Oxidations, Discussion Session
Chairman: Cytochrome P450 Phosphorylation. Stockholm, Sweden, June 1990.
- 12th European Workshop on Drug Metabolism
Basel, Switzerland, September 1990.
- International Ares-Serono Symposium: A Molecular View of Steroid Biosynthesis and Metabolism
Jerusalem, Israel, October 1991.
- 9th New England Membrane Enzyme Meeting, Conference Chairman and Organizer
Centre Harbor, New Hampshire, November 1991.
- Am Soc Pharmacol Exp Therapeutics ASPET-FASEB Symposium: Cytochrome P450-Model for
Integral Membrane Protein Turnover. Anaheim, California, April, 1992.
- Am Assoc Study Liver Diseases (AASLD) Spring Conference: Hepatocyte Differentiation--
Biological and Pathobiological Significance, Mackinac Island, Michigan, June 1992.
- 9th International Symposium on Microsomes and Drug Oxidations
Jerusalem, Israel, July 1992.
- Intl Soc Study Xenobiotics (ISSX) Workshop on Evaluation of Human P450s: Role in Metabolism
Bal Harbour, Florida, November, 1992.
- 10th New England Membrane Enzyme Meeting, Conference Chairman and Organizer
Centre Harbor, New Hampshire, November 1992.
- 2nd Boston Area Receptor Society Meeting
Boston, Massachusetts, May 1993.
- 5th North American Intl Soc Study Xenobiotics (ISSX) Meeting
Tucson, Arizona, October 1993.
- 8th Intl Conf Cytochrome P450: Biochemistry, Biophysics & Molecular Biology
Lisbon, Portugal, October 1993.
- Burroughs-Wellcome Symposium on Endocrine Toxicology
Raleigh-Durham, North Carolina, November 1993.
- Swedish Society of Medicine, Drug Resistance Workshop
Stockholm, Sweden, March 1994.
- Schering Foundation Workshop on Cytochrome P450 Enzymes in Drug Research
Berlin, Germany, March 1994.
- 10th International Symposium on Microsomes and Drug Oxidations
Toronto, Canada, July 1994.
- 6th North American Intl Soc Study Xenobiotics (ISSX) Meeting
Raleigh-Durham, North Carolina, October 1994.
- 12th New England Membrane Enzyme Conference
Woods Hole, Massachusetts, November 1994.
- Amer Soc Clinical Pharmacol Therap Annual Meeting
San Diego, California, March 1995.
- 3rd Boston Area Receptor Society Meeting
Boston, Massachusetts, June 1995.
- Intl Symp DHEA Transformation into Androgens and Estrogens: Intracrinology
Quebec City, Quebec, September 1995.

- 13th New England Membrane Enzyme Conference
Sturbridge, Massachusetts, November 1995.
- Society of Toxicology Annual Meeting
Anaheim, California, March 1996.
- 4th Boston Area Receptor Society Meeting
Boston, Massachusetts, June 1996.
- Gordon Research Conference on Drug Metabolism
New Hampton, New Hampshire, July 1996.
- 11th Intl Symp Microsomes and Drug Oxidations
Los Angeles, California, July 1996.
- 7th North American Intl Soc Study Xenobiotics (ISSX) Short Course on Metabolism in Cancer
Chemotherapy, Chairman and Organizer. San Diego, California, October 1996.
- 14th New England Membrane Enzyme Conference
Sturbridge, Massachusetts, November 1996.
- 5th Boston Area Receptor Society Meeting
Boston, Massachusetts, June 1997.
- Gordon Research Conference on Drug Metabolism
New Hampton, New Hampshire, July 1997.
- 10th Intl Conf Cytochrome P450
San Francisco, California, August 1997.
- Microsomes, Drug Oxidations and Clinical Pharmacology Satellite Symposium
Berlin, Germany, September 1997.
- 2nd World Congr Advances in Oncology
Athens, Greece, October 1997 (*declined*).
- 15th New England Membrane Enzyme Conference
Brownsville, Vermont, November 1997.
- Society of Toxicology, Canada, Signal Transduction Symposium
Montreal, Canada, December 1997.
- Gordon Research Conference on Prolactin
Ventura, California, February 1998.
- 6th Boston Area Receptor Meeting
Boston, Massachusetts, June 1998.
- 12th Intl Symp Microsomes and Drug Oxidations
Montpellier, France, July 1998.
- Serono Symposium: Sex-Steroid Interactions with Growth Hormone
Naples, Florida, October 1998.
- 5th Intl Meeting, Intl Soc Study Xenobiotics (ISSX)
Cairns, Australia, October 1998 (*declined*).
- 1st Intl Symp Molecular Medicine
Crete, Greece, October 1998 (*declined*).
- Novartis Foundation Symposium: Pulsatile Hormone Secretion
London, United Kingdom, March 1999.
- Wellcome Center for Medical Science Symposium
London, United Kingdom, March 1999.
- ENDO '99, Endocrine Society Annual Conference
San Diego, California, June 1999.
- 11th Intl Conference Cytochrome P450
Sendai, Japan, August 1999.
- Hepatocyte Model System Symposium, Bristol-Myers Squibb
Princeton, New Jersey, October 1999.
- 28th Intl Symp Growth Hormone and Growth Factors in Endocrinology and Metabolism
Boston, Massachusetts, October 1999.
- 17th New England Membrane Enzyme Conference
Woods Hole, Massachusetts, November 1999.
- BIO2000 TechTransfer Forum
Boston, Massachusetts, March 2000.

- 4th Intl Conf Drug-Drug Interactions
Baltimore, Maryland, June 2000 (*declined*).
- ENDO 2000, Symposium on Growth Hormone and Prolactin Signal Transduction
Toronto, Canada, June 2000.
- 13th Intl Symp Microsomes and Drug Oxidations
Stresa, Italy, July 2000.
- Institute of Scientific Exchange Conf: Early Toxicity Screening in Drug Discovery
Baltimore, Maryland, October 2000.
- Genetic Toxicology Association Annual Meeting
Delaware, October 2000.
- 5th World Cong Advances in Oncology
Crete, Greece, October 2000 (*declined*).
- 11th Congress, Intl Society of Endocrinology
Sydney, Australia, October 2000 (*declined*).
- Toxicology Forum, FDA Office of Women's Health Program
Washington DC, February 2001.
- Rozman Symposium Lecture, Delaware Valley Drug Metabolism Discussion Group
Bucks County, Delaware, May 2001.
- 12th Intl Conference Cytochrome P450
La Grande Motte, France, September 2001 (*declined*).
- ISSX 2001 International Symposium
Munich, Germany, October 2001 (*declined*).
- 4th Intl Symp Molecular Medicine
Crete, Greece, October 2001 (*declined*).
- Japan Neuroendocrine Society Annual Meeting
Tokyo, Japan, October 2001 (*declined*).
- 10th Intl Conf Gene Therapy of Cancer
San Diego, December 2001.
- New England Drug Metabolism Discussion Group Meeting
Cambridge, Massachusetts, January 2002.
- ENDO 2002, Symposium on Growth Hormone and Prolactin Signaling
San Francisco, June 2002.
- American Cancer Society Schilling Conference 2002: Tumors as Outlaw Organs
Santa Cruz, California, September 2002.
- Intl Congress on Hormonal Steroids and Hormones and Cancer
Fukuoka City, Japan, October 2002 (*declined*).
- 7th World Congress on Advances in Oncology
Crete, Greece, October 2002 (*declined*).
- Growth Hormone – Insulin-like Growth Factor Symposium 2002
Boston, Massachusetts, October 2002.
- American Assoc Pharmaceutical Scientists (AAPS) Annual Meeting
Toronto, Canada, November 2002.
- British Toxicology Society Annual Congress
Edinburgh, Scotland, April 2003.
- 13th Intl Conf Cytochrome P450
Prague, Czech Republic, July 2003.
- Superfund Basic Research Program, Annual Mtg
Dartmouth, New Hampshire, November 2003.
- Experimental Biology 2004, ASPET Symposium: Cancer Chemotherapy and Drug Metabolism
Washington DC, April 2004.
- 3rd PCB Workshop 2004
Univ. of Illinois, Champaign/Urbana, June 2004.
- Pharmaceutical Education Associates Prodrug Symposium
Philadelphia, Pennsylvania, June 2004.
- 15th Intl Sympo Microsomes and Drug Oxidations
Mainz, Germany, July 2004.

- 43rd Ann Mtg European Soc Pediatric Endocrinology
Basel, Switzerland, September 2004.
- 1st Ann *In Vitro* ADMET Technologies Conf
Cambridge, Massachusetts, October 2004.
- 7th Intl Symp Molecular Medicine
Crete, Greece, October 2004 (*declined*).
- North Jersey ACS Drug Metabolism Discussion Group Symposium
Somerset, New Jersey, October 2004 (*declined*).
- Children's Oncology Group/ ASCO Symposium: Apoptosis and Cancer Therapy
Atlanta, Georgia, November 2004.
- 6th Intl Workshop Pharmacodynamics of Anti-cancer Agents
Venice, Italy, November 2004.
- Pharmaceutical Education Associates Symposium on Prodrugs and Soft Drugs
Philadelphia, Pennsylvania, June 2005 (*declined*).
- Int'l Conf on Gene and Drug Therapy
Crete, Greece, September 2005 (*declined*).
- 22nd New England Membrane Enzyme Group Conference
Sturbridge, Massachusetts, November 2005.
- Prolactin Family Gordon Research Conference
Ventura, California, January 2006.
- Israeli Society of Gene Therapy, 4th Annual Conference
Tel Aviv, Israel, March 2006.
- ENDO 2006, Endocrine Society Annual Meeting
Boston, Massachusetts, June 2006.
- 16th Intl Sympos Microsomes and Drug Oxidations
Budapest, Hungary, September 2006.
- Drug and Gene-based Therapeutics
Crete, Greece, September 2006 (*declined*).
- 11th World Congress on Advances in Oncology
Crete, Greece, October 2006 (*declined*).
- American Assoc Pharmaceutical Scientists (AAPS) Annual Mtg
San Antonio, Texas, November 2006.
- 23rd New England Membrane Enzyme Group Conference
Sturbridge, Massachusetts, November 2006.
- 4th Copenhagen Workshop on Endocrine Disrupters
Copenhagen, Denmark, May 2007.
- 15th Intl Conf Cytochromes P450: Biochemistry, Biophysics, Functional Genomics
Bled, Slovenia, June 2007.
- 10th Intl Symp Molecular Medicine
Crete, Greece, October 2007.
- American Assoc Pharmaceutical Scientists (AAPS) Annual Mtg
San Diego, November 2007.
- Amer Soc Clin Pharmacol and Therap (ASCP) Annual Meeting
Orlando, Florida, April 2008
- 17th Intl Sympos Microsomes and Drug Oxidations,
Saratoga Springs, NY, July 2008

INVITED SPEAKER - DEPARTMENTAL SEMINAR SERIES:

- 1980 - Bristol-Myers Research Labs, Dept. of Medicinal Chemistry
- 1980 - Weizmann Institute of Science, Dept. of Biophysics
- 1980 - Tel Aviv University, Dept. of Biochemistry
- 1981 - Harvard University, Dept. of Biochemistry and Molecular Biology
- 1982 - Yale University School of Medicine, Dept. of Pharmacology
- 1982 - University of Pennsylvania, Dept. of Pharmacology
- 1982 - Dana-Farber Cancer Institute, Division of Cancer Pharmacology

1982 - The Rockefeller University
 1982 - Harvard Medical School, Dept. of Biological Chemistry
 1982 - Brown University, Division of Biology and Medicine
 1983 - Hoffman-La Roche, Inc., Dept. of Chemotherapy
 1984 - University of Connecticut Health Center, Dept. of Pharmacology
 1984 - Johns Hopkins University, Dept. of Chemistry
 1985 - National Cancer Institute, Laboratory of Molecular Carcinogenesis
 1986 - New York University, Dept. of Cell Biology
 1986 - DuPont de Nemours & Co., Cardiovascular Group, Wilmington
 1987 - Univ. of Medicine and Dentistry of New Jersey, Dept. of Biochemistry
 1987 - University College, London, Dept. of Biochemistry
 1987 - University of Massachusetts Amherst, Dept. of Biochemistry
 1988 - Harvard School of Public Health, Laboratory of Toxicology
 1988 - W. R. Grace & Company, Lexington, Massachusetts
 1988 - University of Mainz, West Germany, Institute of Toxicology
 1989 - University of Rochester School of Medicine, Dept. of Biophysics
 1989 - Wadsworth Center Laboratories, State of New York, Dept. of Health, Albany
 1989 - Boston University Medical Center, Dept. of Pharmacology
 1989 - Tufts University School of Medicine, Dept. of Biochemistry
 1989 - St. Jude Children's Research Hospital, Pharmaceutical Division
 1990 - University of Massachusetts Medical Center Worcester, Dept. of Biochemistry & Molec Biology
 1990 - University of Louisville School of Medicine, Dept. of Biochemistry
 1991 - Rhode Island Hospital, Dept. of Pathology
 1992 - University of Pennsylvania, Dept. of Pharmacology
 1992 - Cornell Medical School, Div. of Digestive Diseases
 1992 - Boston University Medical Center, Dept. of Pharmacology
 1992 - Chicago Medical School, Dept. of Pharmacology and Molecular Biology
 1992 - McArdle Laboratory, University of Wisconsin, Dept. of Oncology
 1992 - Tufts University School of Medicine, Dept. of Pharmacology and Experimental Therapeutics
 1992 - Albert Einstein College of Medicine Liver Center
 1992 - Wadsworth Research Laboratories, State of New York, Dept. of Health, Albany
 1992 - Massachusetts General Hospital, Dept. of Surgery and Shriners Hospital Liver Center
 1993 - Moffitt Cancer Center, Univ. of South Florida
 1993 - Boston University, Dept. of Biology
 1993 - George Washington University Medical School, Dept. of Biochemistry and Molecular Biology
 1993 - Institute of Chemical Toxicology, Wayne State University
 1993 - Massachusetts General Hospital East, Neurosciences Center
 1993 - Cornell Medical School, Div. of Digestive Diseases
 1994 - University of Uppsala, Dept. of Biochemistry
 1994 - Boston University, Center for Advanced Biotechnology and Cell and Molecular Biology
 1995 - Scripps Research Foundation, Division of Biochemistry
 1995 - National Cancer Institute, Div. of Cancer Therapeutics, Drug Discovery Program
 1995 - Genzyme Corporation, Div. of Molecular Biology and Gene Therapy
 1995 - Cancer Research Center, Laval University, Quebec
 1995 - University of Toronto, Dept. of Pharmacology
 1995 - Massachusetts General Hospital Cancer Center, Div. of Hematology/Oncology
 1996 - Boston University Medical Center, Dept. of Pharmacology
 1996 - New York University, Dept. of Cell Biology
 1996 - Genetics Institute, Preclinical Pharmacokinetics Division
 1996 - Boston University Medical Center, Dept. of Biochemistry
 1997 - Fuji ImmunoPharmaceuticals Corporation, Div. of Drug Development
 1997 - University of Virginia Health Sciences Center, Div. of Endocrinology
 1997 - University of Kentucky at Lexington, Dept. of Toxicology
 1997 - Dartmouth Medical School, Dept. of Pharmacology
 1997 - Oxford BioMedica, Oxford, United Kingdom
 1997 - Yale University Medical School, Div. of Gastroenterology

- 1998 - Univ. of Massachusetts Med Center., Worcester, Dept. of Pharmacology & Molecular Toxicology
- 1998 - Boston University Medical Center, Cancer Research Center, Hematology-Oncology Division
- 1998 - Dana Farber Cancer Institute, Clinical Pharmacology STAMP Research Group
- 1998 - National Cancer Institute, Developmental Therapeutics Program
- 1999 - McGill University, Montreal Children's Hospital Research Institute
- 1999 - Vion Pharmaceuticals, Biology Department, New Haven
- 1999 - Metabasis Therapeutics, Inc., San Diego
- 2000 - Eisai Research Institute, Andover, Massachusetts, Division of Metabolism and Pharmacokinetics
- 2000 - X-Ceptor Therapeutics, Inc., San Diego
- 2000 - Boston University Medical Center, Dept. of Pathology
- 2000 - DuPont Pharmaceuticals, Division of Toxicology, Newark, Delaware
- 2000 - Children's Hospital, Harvard Medical School, Endocrine Division
- 2000 - ArQule, Inc., Dept. of Biology, Woburn, Massachusetts
- 2000 - 3M Medical Department, Toxicology Tech Forum, St. Paul, Minnesota
- 2000 - Wyeth-Ayerst Research, Medical Affairs, Philadelphia, Pennsylvania
- 2000 - Penn State University, Center for Molecular Toxicology
- 2001 - Rockefeller University, Division of Endocrinology and Reproductive Biology and Population Council
- 2001 - Wyeth-Ayerst Drug Metabolism Division, Princeton, New Jersey
- 2001 - Hadassah Medical School, Gene Therapy Center, Jerusalem, Israel
- 2001 - Hebrew University, Institute of Life Sciences, Jerusalem, Israel
- 2001 - University of London, Dept. of Pharmaceutical and Biological Chemistry, London
- 2001 - Baylor College of Medicine, Dept. of Pharmacology, Houston
- 2001 - Boston University Medical Center, Dept. of Pharmacology
- 2001 - Absorption Systems, Dept. of Drug Metabolism and Pharmacokinetics, Exton, Pennsylvania
- 2001 - Pfizer Pharmaceuticals, Dept. of Pharmacokinetics, Dynamics and Metabolism
- 2001 - Metabasis Therapeutics, Dept. of Biological Sciences, San Diego
- 2002 - Boston University Medical Center, Dept. of Medicine, Hematology/Oncology Section
- 2003 - Oncology Research and Development Group, AstraZeneca, Waltham, Massachusetts
- 2003 - University of Alabama, Birmingham, Dept. of Cell Biology
- 2003 - University of Dundee Biomedical Research Centre, Scotland
- 2003 - Astex Technology, Cambridge, England
- 2003 - Boston University, School of Dental Medicine, Dept. of Molecular and Cell Biology
- 2003 - Tufts University, School of Medicine, Dept. of Pharmacology and Experimental Therapeutics
- 2004 - Wadsworth Center, NY State Dept. of Health, Albany, New York
- 2004 - Boston Medical Center, GI Grand Rounds, Division of Gastroenterology
- 2004 - Austrianova, Dept. of Science and Technology, Vienna, Austria
- 2004 - Padua University, Dept. of Oncology and Surgical Sciences, Padua, Italy
- 2005 - Univ. of Connecticut, Dept. of Pharmaceutical Sciences, School of Pharmacy, Storrs, CT
- 2006 - Univ. of Texas Medical Branch, Galveston, Dept. of Pharmacology and Toxicology
- 2006 - Savad Institute of Gene Therapy, Hadassah University Hospital, Jerusalem, Israel
- 2007 - Hebrew University, Dept. of Biological Chemistry, Jerusalem, Israel
- 2007 - Hebrew University, Faculty of Agriculture, Food and Environmental Quality Sciences, Rehovot, Israel
- 2007 - University of Rhode Island, Center for Molecular Toxicology, College of Pharmacy
- 2007 - Medical College of Wisconsin, Dept. of Pharmacology and Toxicology
- 2007 - Karolinska Institute, Dept. of Physiology and Pharmacology, Stockholm, Sweden
- 2007 - University of Iowa, Dept. of Occupational and Environmental Health

WAXMAN LABORATORY RESEARCH SUPPORT

(I) MAJOR RESEARCH GRANTS (Principal Investigator)

1. National Institutes of Health Grant DK 33765, 4/1984 - 1/2008.
"Biochemistry of Cytochrome P-450: Biosynthetic Isozymes", 4/1984 - 3/1987.
"Cytochrome P-450: Endogenous Substrate Metabolism", 4/1987 - 1/2008.
2. National Institutes of Health Grant CA49248, 7/1991 - 4/2009.
"Hepatic Metabolism of Anticancer Drugs".
3. National Institutes of Health Grant ES07381, 5/1995 - 3/2010.
"Activation of Orphan Receptors by Chlorinated Hydrocarbons", 5/1995-3/2000.
"PPAR, Hormones and Xenobiotics", 4/2000-3/2005.
"Nuclear Receptors and Gonadal Toxicity of Xenochemicals", 4/2005-3/2010.
4. National Science Foundation, EHR DGE 0654108, 7/ /2007 - 6/2012.
"IGERT: Integrating Computational Science into Research in Biological Networks"
Gary Benson, PI; David J. Waxman, co-PI. *Expected to be funded.*
5. National Institutes of Health Grant DK53767, 8/1999 - 7/2004.
"NADPH P450 Reductase: Thyroid Hormone Regulation".
6. American Cancer Society Grant, BC-462/CN-14, 7/1984 - 6/1998.
"Oxidative Metabolism of Xenobiotics".
7. American Cancer Society Grant, CH-487, 1/1990 - 12/1993.
"Mechanisms of Acquired Drug Resistance".
8. National Institutes of Health Grant CA19589, 9/1985 - 4/1991.
"Biochemical Studies of Human Liver Folylpolylglutamate Synthetase".

(II) OTHER RESEARCH FUNDING

1. Research Corporation Award, 11/1983.
"Biochemical Studies of Mammalian Liver Sulfoxide Reductase".
2. American Cancer Society Grant, Massachusetts Division, 11/1983 - 10/1984.
"Oxidative Metabolism of Steroids and Foreign Compounds".
3. Biomedical Research Support Grant, 11/1983 - 10/1984.
"Sex-related Differences in Xenobiotic Metabolism".
4. Biomedical Research Support Grant, 7/1985 - 9/1985.
"Metabolism of Antifolate Drugs".
5. Biomedical Research Support Grant, 11/1986 - 10/1987.
"Interactions of Anti-cancer Drugs with Cytochrome P-450".
6. Biomedical Research Support Grant, 7/1991 - 6/1992.
"Activation of Liver Gene Expression and Peroxisome Proliferation by the Peroxisome Proliferator Receptor".
7. Hofmann-La Roche Research Grant, 12/1983 and 12/1984.
8. Mathers Research Foundation Grant, 2/1986.
9. W.R. Grace/New England Deaconess Hospital Grant, 4/1989.
10. National Cancer Institute/SAIC Frederick Cancer Research and Development.
"Human Cytochrome P450 Expression in Tumor Cell Lines", 10/1995.

- "P450 Expression in NCI Tumor Cell Lines", 6/1997.
- 11. National Institutes of Health Grant (S10) RR11397, 8/1996, Co-P.I.
"Acquisition of a Molecular Imager".
- 12. Genetics Institute Research Contract, 10/1996.
"Drug-Drug Interactions of IL-11 and Cyclophosphamide".
- 13. 3M Corporation Research Contract, 12/2000.
"Xenochemical Receptor trans-Activation by Perfluorooctane-based Chemicals".
- 14. 3M Corporation Research Contract, 10/2001, 10/2002.
"Trans-activation of Xenoreceptors by Perfluorochemicals".
- 15. NSF IGERT Grant DGE-0654108, 7/2007-6/2012, DJ Waxman, co-PI.
"Integrating Computational Science into Research in Biological Networks".

(III) POSTDOCTORAL, GRADUATE and UNDERGRADUATE FELLOWSHIP AWARDS

- 1. Damon Runyon-W. Winchell Cancer Fund - Postdoct. Fellowship, D.J. Waxman, 9/1980-8/1981.
NRSA - Postdoctoral Fellowship, D.J. Waxman (F32) GMES 07935, 9/1981-6/1983.
"Mechanism-based Inactivation of Cytochrome P-450".
- 2. NRSA - Postdoctoral Fellowship, E.J. Holsztynska (F32) AM 07648, 6/1985-5/1988.
"Biochemistry and Regulation of Cholesterol 7 α -Hydroxylase".
- 3. NRSA - Postdoctoral Fellowship, G.A. LeBlanc (F32) CA 08259, 3/1987-3/1990.
"Cytochrome P-450-Anticancer Drug Interactions".
- 4. American Heart Association - Postdoctoral Fellowship, S.S. Sundseth, 7/1989-6/1991.
"Biochemistry and Regulation of Cholesterol 7 α -Hydroxylase".
- 5. Deutsche Forschungsgemeinschaft - Postdoctoral Fellowship, G. F. Weber, 1/1990-6/1991.
"Biochemical Pharmacology of Anticancer Drugs".
- 6. Canadian Assoc Gastroenterology - Postdoctoral Fellowship, T.K.H. Chang 7/1991-6/1992.
Canadian Liver Foundation - Postdoctoral Fellowship, T.K.H. Chang, 7/1992-6/1994.
"Bioactivation of Cancer Chemotherapeutic Drugs by Liver P450 Enzymes".
- 7. Assoc pour la Recherche Contre le Cancer (ARC) - Postdoctoral Fellowship, Y. Jounaidi,
1/1996-12/1996. "Retroviral Expression of P450 Genes: Cancer Gene Therapy".
- 8. Howard Hughes Undergraduate Summer Research Fellowship, J. Matias, 1996.
"Modulation of Alternative Pathways of Ifosfamide Metabolism".
- 9. National Science Foundation Undergraduate Summer Research Fellowship, R. Anard, 1996.
"Activation and Deactivation of Ifosfamide by Cytochrome P450".
- 10. Assoc pour la Recherche Contre le Cancer (ARC) - Postdoctoral Fellowship, E. Brain,
2/1996-11/1996. "Modulation of Oxazaphosphorine Metabolism: Preclinical Models".
- 11. National Science Foundation Undergraduate Summer Research Scholarship, H. Burden, 1997.
"Role of CYP3A in Anticancer Drug Activation".
- 12. Ernst Schering Research Foundation Postgraduate Fellowship, Y. Jounaidi, 10/97-9/99.
"Cytochrome P450-based Cancer Gene Therapy".

13. Howard Hughes. Undergraduate Summer Research Fellowship, L. Lin, 1999.
"Retroviral Packaging in Transient and Stable Cell Lines".
14. NRSA - Postdoctoral Fellowship, C.H. Hurst (F32) ES 011105, 4/2001-3/2004.
"Apoptosis Suppression by Peroxisome Proliferators".
15. NRSA - Postdoctoral Fellowship, T. Su (F32) CA 10139, 4/2004 - 6/2006.
"Apoptosis Modulation in Prodrug Activation Gene Therapy".
16. National Cancer Institute Minority Supplement Award, E. Manley, 8/2004-6/2009.
"Hepatic Metabolism of Anti-cancer Drugs".
17. Belgian American Educational Foundation (BAEF), Franqui Foundation Fellowship Award, V. Wauthier, 9/2006-8/2007. "Role of GH in the Regulation of Sex-specific Liver P450 Genes".

THESIS MENTORSHIP - Undergraduate

1. Wankin Yu, Harvard University. (1979) "Biochemical studies on penicillin action: isolation and characterization of linear uncross-linked peptidoglycan derived from *Bacillus subtilis*".
Publication: (1980) J Biol Chem **255**, 11577-11587.
2. David M. Lindgren, Harvard University. (1979) "Purification of several of the high molecular weight penicillin-binding proteins from *Bacillus subtilis* and *Staphylococcus aureus*".
Publication: (1981) J Bacteriol **148**, 950-955.
3. Jocelyne R. Matias, Boston University. (1997) "Identification of cytochrome-P450 isozymes in human tumor cell lines".
4. Heather Burden, Boston University. (1998) "P450 enzyme CYP3A5 as a candidate for gene therapy in conjunction with the anticancer drugs cyclophosphamide and ifosfamide".
5. Ira S. Winer, Boston University. (1999) "The effect of exogenous Bcl-2 family protein expression on the chemosensitivity of mouse NIH-3T3 fibroblasts".
6. Anthony J. Patrello, Boston University. (2000) "Characterization and tagging of the closely related STAT5a and STAT5b".
7. Luke Lin, Boston University. (2000) "Retroviral packaging in transient and stable cell lines".

THESIS MENTORSHIP - Masters

- 1/2. Katja Gustafsson and Pernille Drewes, The Royal Danish School of Pharmacy and Boston University, M.A. (1996) "Modulation of the pharmacokinetics of the activation and deactivation pathways of the anticancer prodrugs cyclophosphamide and ifosfamide in the rat".
Publications: (1998) Br J Cancer **77**, 1768-1776; (1999) J Pharm Exp Therap **288**, 928-937
3. Blossom Y.-P. Wu, Boston University, M.A. (1998)
"Functional significance of tyrosine phosphatases in growth hormone signaling".
4. Erin K. Maloney, Boston University, M.A. (1999)
"P450-mediated metabolism of trichloroethylene and activation of the peroxisome proliferator-activated receptor (PPAR)".
Publication: (1999) Toxicol Appl Pharmacol **161**, 209-218.
5. Suneet K. Bains, Boston University, M.A. (2000)

"Growth hormone-dependent intracellular localization of STAT5b".

6. Jack Lin, Boston University, M.A. (2001)
"Metabolism of anti-cancer drugs cyclophosphamide and ifosfamide by site-specific CYP2B1 mutants".
Publication: (2004) *Molec Pharmacol* **65**, 1278-1285.
7. Alexander Baldwin, Boston University, M.A. (2002) "Identification of novel enzyme-prodrug combinations for use in cytochrome P450 gene therapy".
Publication: (2003) *Arch Biochem Biophys* **409**, 197-206.
8. Hong Lu, Biomolecular Pharmacology Program, Boston University, M.A. (2005) "Activation of Methoxymorpholinyl doxorubicin".
Publication: (2005) *Molec Pharmacol* **67**, 212-219.
9. Caitlin O'Connor, Cell and Molecular Biology, Boston University (2006) "Growth hormone regulation of sex-dependent rodent and human liver cytochrome P450 genes and the desensitization of GH signal transduction".
Publication: (2006) *Molec Endocrinol* **20**, 2613-2629.

THESIS MENTORSHIP - Ph.D.

1. Hee K. Choi, Cell & Molecular Biology, Boston University, Ph.D. (2000).
"The role of STAT5b in growth hormone-dependent, male-specific liver gene expression".
Publications: (1999) *Endocrinology* **140**, 5126-5135; (2000) *Endocrinology* **141**, 3245-3255.
(2000) *GH & IGF Research* **10**, Suppl B, S1-S8.
2. Yuanchun Zhou, MCBB Program, Boston University, Ph.D. (2000).
"Inhibitory cross-talk between PPAR α and STAT5b signaling pathways".
Publications: (1996) *Molec Pharmacol* **50**, 67-74; (1998) *Environ Health Perspect* **106**, 983-988;
(1999) *J Biol Chem* **274**, 2672-2681; (1999) *J Biol Chem* **274**, 29874-29882.
(2002) *Toxicol Appl Pharmacol* **182**, 1-10.
3. Jodi E. D. Hecht, Cell & Molecular Biology, Boston University, Ph.D. (2002).
"In vitro and in vivo models for cytochrome P450-based anti-cancer gene therapy".
Publications: (1998) *Canc Res* **58**, 4391-4401; (2000) *Meth Molec Med* **35**, 77-83.
(2000) *Meth Molec Med* **35**, 85-94; (2000) *Meth Molec Med* **35**, 95-105.
(2000) *Meth Molec Med* **35**, 107-118.
4. Pamela S. Schwartz, MCBB Program, Boston University, Ph.D. (2002).
"Impact of apoptotic factors on cytochrome P450-dependent cyclophosphamide anti-cancer activity".
Awards: (2001) Boston University Science Day, Technology Transfer Award.
Publications: (2001) *Molec Pharmacol* **60**, 1268-1279; (2002) *Canc Res* **62**, 6928-6937.
(2003) *Canc Gene Ther* **10**, 571-582; (2003) *Canc Res* **63**, 8563-8572.
5. Christopher Wiwi, Cell & Molecular Biology, Boston University, Ph.D. (2004).
"Growth hormone-regulated hepatic nuclear factors regulate the sex-dependent expression of liver cytochromes P450".
Awards: (1999) NIH-sponsored Endocrinology Training Grant Fellowship award
(2001) 19th New England Membrane Enzyme Conference poster award
(2002) ENDO 2002 – Endocrine Society Graduate Student Travel Award
Publications: (2004) *Molec Endocrinol* **18**, 1985-1987; (2004) *Growth Factors* **22**, 79-88.
(2005) *J Biol Chem* **280**, 3259-3268; (2006) *Biochem J* **397**, 159-168.
6. Jonathan Shipley, MCBB Program, Boston University, Ph.D. (2005).

"Cross-talk between hormone-regulated transcription factors, STAT5b and ER, and xenochemical receptors, PPAR and AHR".

Publications: (2003) Molec Pharmacol **64**, 1-10; (2004) Toxicol Appl Pharmacol **199**, 275-284.
(2004) Toxicol Sci **80**, 151-160; (2006) Toxicol Appl Pharmacol **213**, 87-97.

7. Karl Clodfelter, Bioinformatics Program, Boston University, Ph.D. (2007).
"Computational analysis of cytochrome P450 structure and expression"
Publications: (2004) Molec Endocrinol **18**, 747-760; (2006) Molec Endocrinol **20**, 1333-1351.
(2006) Biochemistry **45**, 9393-9407; (2007) Physiol Genomics, submitted.
8. Minita Gupte Holloway, MCBB Program, Boston University, Ph.D. in progress.
Awards: (2006) I. Alden Macchi Award for Excellence in Endocrinology & Regulatory Biology
(2007) NIH-sponsored NICHD Training Grant Fellowship award
Publications: (2004) Molec Endocrinol **18**, 1975-1987; (2006) Molec Endocrinol **20**, 647-660.
(2006) Molec Endocrinol **20**, 1333-1351; (2007) Endocrinol **148**, 1977-1986.
9. Jie Ma, MCBB Program, Boston University, Ph.D. in progress.
Awards: (2005) New England Membrane Enzyme Meeting, Best Poster Award
(2007) Boston University Science and Engineering Day, Founder's Award
Publications: (2007) Molec Canc Ther, submitted.
10. Tara Peters, MCBB Program, Boston University, Ph.D. in progress.
Awards: (2005) NIH-sponsored NICHD Training Grant Fellowship award
11. Eugene Manley, MCBB Program, Boston University, Ph.D. in progress.
Awards: (2004) National Cancer Institute Minority Supplement Award, five years support.
12. Joshua Doloff, MCBB Program, Boston University, Ph.D. in progress.
Awards: (2007) Boston University Science and Engineering Day, Technology Development Award.
13. Gregory Miles, Bioinformatics Program, Boston University, Ph.D. in progress.
14. Kendrick Goss, MCBB Program, Boston University, Ph.D. in progress.
15. Mathew Belmonte, Cell & Molecular Biology, Boston University, Ph.D. in progress.

TEACHING EXPERIENCE:

A. Course Lecturer, Harvard Medical School:

Biochemistry 201/BCMP 201, Comprehensive Biochemistry

Fall 1984, 1985, 1986, 1987, 1988

Biochemistry 700B/221, Advanced General Biochemistry (Medical School Curriculum)

Fall 1984, 1985, 1986

Biophysics 300, Introduction to Biophysics, Fall 1984, 1985, 1986, 1987

BCMP 202, Eukaryotic Membranes, Spring 1989

BCMP 211, Membrane Structure and Function, Fall 1989, 1991

MFHOS, Metabolism and Physiology (Medical School Curriculum)

Fall 1987, 1988, 1989, 1990, 1991, 1992, 1993

BCMP 218/Toxicology 205, Principles of Toxicology (School of Public Health)

Fall 1988, 1989

Medical Pharmacology, Spring 1987

BCMP 212, Cellular and Molecular Endocrinology, Spring 1990

BCMP 207, Molecular Mechanisms of Drug Action, Spring 1990, 1992

Molecular Basis of Disease (Markey Fellows Medical Biochemistry), Spring 1992, 1993

B. Course Lecturer, Boston University:

BI556, Membrane Biochemistry (Course Director): Spring 1995, Fall 1996, 1998, 2001, 2003, 2005
MB722, Advanced Biochemistry: Spring 2004, 2005
BF820, Research Opportunities in Bioinformatics: Spring 2006, Fall 2006
BUSPH/EH830, Topics in Environmental Health: Spring 1995, 1997
BUSM/PM7000, Molecular Neurobiology and Pharmacology: Spring 2003, 2004, 2005, 2006, 2007

C. Postdoctoral Fellows under training in the laboratory:

1983-1984 (1); 1984-1985 (2); 1985-1986 (3); 1986-1987 (4)
1987-1989 (5); 1989-1990 (6); 1990-1995 (7); 1995-1996 (8)
1996 – present, 6 – 10 postdoctoral trainees each year
Total Number of Individuals: >35

D. Graduate Student mentoring:

Ph.D. Thesis students: 15 (1994-present)
Masters Thesis students: 9 (1995-present)
Rotation training Ph.D. students:
9 (1985-1993), 6 (1994-1995), 5 (1995-1996), 5 (1996-1997),
4 (1997-1998), 2 (1998-1999), 5 (1999-2000), 3 (2001-2002),
3 (2002-2003), 5 (2003-2004), 5 (2004-2005), 3 (2005-2006), 3 (2006-2007)

D. Undergraduate Students: research training, internships or thesis research programs

1983 - 1993: 6 students; 1994 - 1996: 6 students
1996 - 1997: 2 students; 1997 - 1998: 3 students
1998 - 1999: 3 students; 1999 - 2000: 2 students
2004 - 2007: 1-2 students/year

BIBLIOGRAPHY

(I) ORIGINAL JOURNAL ARTICLES

1. Waxman DJ, Strominger JL. Cleavage of a COOH-terminal hydrophobic region from D-alanine carboxypeptidase, a penicillin-sensitive bacterial membrane enzyme: characterization of active, water-soluble fragments. (1979) *J Biol Chem* 254, 4863-4875.
2. Waxman DJ, Strominger JL. Cephalosporin-sensitive penicillin-binding proteins of *Staphylococcus aureus* and *Bacillus subtilis* active in the conversion of [¹⁴C]penicillin G to [¹⁴C]phenylacetylglutamate. (1979) *J Biol Chem* 254, 12056-12061.
3. Yocum RR, Waxman DJ, Rasmussen JR, Strominger JL. Mechanism of penicillin action: penicillin and substrate bind covalently to the same active site serine of two bacterial D-alanine carboxypeptidases. (1979) *Proc Natl Acad Sci* 76, 2730-2734.
4. Waxman DJ, Yocum RR, Strominger JL. Penicillins and cephalosporins are active site-directed acylating agents: evidence in support of the substrate analog hypothesis. (1980) *Phil Trans R Soc Lond* B289, 257-271.
5. Waxman DJ, Strominger JL. Sequence of active site peptides from the penicillin-sensitive D-alanine carboxypeptidase of *Bacillus subtilis*: mechanism of penicillin action and sequence homology to β -lactamases. (1980) *J Biol Chem* 255, 3964-3976.
6. Waxman DJ, Yu W, Strominger JL. Linear, uncrosslinked peptidoglycan secreted by penicillin-treated *Bacillus subtilis*: characterization as a substrate for penicillin-sensitive D-alanine carboxypeptidase. (1980) *J Biol Chem* 255, 11577-11587.
7. Waxman DJ. Structural studies of penicillin-sensitive D-alanine carboxypeptidase. (1980) *Ph.D. Dissertation*, Harvard University.
8. Moews PC, Knox JR, Waxman DJ, Strominger JL. Comparison of predicted secondary structures of β -lactamases and penicillin-sensitive D-alanine carboxypeptidases. (1981) *Int J Prot Pept Res* 17, 211-218.
9. Waxman DJ, Strominger JL. Limited proteolysis of the penicillin-sensitive D-alanine carboxypeptidase purified from *Bacillus subtilis* membranes. Active, water-soluble fragments generated by cleavage of a COOH-terminal membrane anchor. (1981) *J Biol Chem* 256, 2059-2066.
10. Waxman DJ, Strominger JL. Primary structure of the COOH-terminal membranous segment of a penicillin-sensitive enzyme purified from two bacilli. (1981) *J Biol Chem* 256, 2067-2077.
11. Waxman DJ, Lindgren DM, Strominger JL. High-molecular weight penicillin-binding proteins from membranes of bacilli. (1981) *J Bacteriol* 148, 950-955.
12. Yocum RR, Amanuma H, O'Brien TA, Waxman DJ, Strominger JL. Penicillin is an active site inhibitor for four genera of bacteria. (1982) *J Bacteriol* 149, 1150-1153.
13. Waxman DJ, Amanuma H, Strominger JL. Amino acid sequence homologies between *Escherichia coli* penicillin-binding protein 5 and class A β -lactamases. (1982) *FEBS Lett* 139, 159-163.
14. Light DR, Waxman DJ, Walsh C. Studies on the chirality of sulfoxidation catalyzed by bacterial flavoenzyme cyclohexanone monooxygenase and hog liver flavin adenine dinucleotide-containing monooxygenase. (1982) *Biochemistry* 21, 2490-2498.
15. Waxman DJ, Light DR, Walsh C. Chiral sulfoxidations catalyzed by rat liver cytochromes P-450. (1982) *Biochemistry* 21, 2499-2507.

16. Waxman DJ, Walsh C. Phenobarbital-induced rat liver cytochrome P-450. Purification and characterization of two closely related isozymic forms. (1982) J Biol Chem **257**, 10446-10457.
17. Waxman DJ, Walsh C. Catalytic and structural properties of two new cytochrome P-450 isozymes from phenobarbital-induced rat liver: comparison to the major induced isozymic form. (1982) In: Hietanen E, et al., eds. Cytochrome P-450. Biochemistry, biophysics and environmental implications. New York: Elsevier/Biomedical Press, 311-316.
18. Waxman DJ, Ko A, Walsh C. Testosterone hydroxylations catalyzed by purified rat liver cytochrome P-450 isozymes. (1982) In: Hietanen E, et al., eds. Cytochrome P-450. Biochemistry, biophysics and environmental implications. New York: Elsevier/Biomedical Press, 381-386
19. Waxman DJ, Walsh C. Cytochrome P-450 isozyme 1 from phenobarbital-induced rat liver: Purification, characterization and interactions with metyrapone and cytochrome b₅. (1983) Biochemistry **22**, 4846-4855.
20. Waxman DJ, Ko A, Walsh C. Regioselectivity and stereoselectivity of androgen hydroxylations catalyzed by cytochrome P-450 isozymes purified from phenobarbital-induced rat liver. (1983) J Biol Chem **258**, 11937-11947.
21. Waxman DJ. Rat hepatic cytochrome P-450 isoenzyme 2c: identification as a male-specific, developmentally-induced steroid 16 α -hydroxylase and comparison to a female-specific cytochrome P-450 isoenzyme. (1984) J Biol Chem **259**, 15481-15490.
22. Tauber AI, Wright J, Higson FK, Edelman SA, Waxman DJ. Purification and characterization of the human neutrophil NADH-cytochrome b₅ reductase. (1985) Blood **66**, 673-678.
23. Waxman DJ, Dannan GA, Guengerich FP. Regulation of rat hepatic cytochrome P-450: age-dependent expression, hormonal imprinting and xenobiotic inducibility of sex-specific isoenzymes. (1985) Biochemistry **24**, 4409-4417.
24. Frey AB, Waxman DJ, Kreibich G. The structure of phenobarbital-inducible rat liver cytochrome P-450 isoenzyme PB-4: production and characterization of site-specific antibodies. (1985) J Biol Chem **260**, 15253-15265.
25. Sehgal RK, Sengupta SK, Waxman DJ, Tauber AI. Enzymatic and chemical reduction of 2-deaminoactinomycins to free radicals. (1985) Anti-cancer Drug Design **1**, 13-25.
26. Rampersaud A, Waxman DJ, Ryan DE, Levin W, Walz FG Jr. Microheterogeneity of a male-specific rat hepatic cytochrome P-450. Existence of three allozymic forms. (1985) Arch Biochem Biophys **243**, 174-183.
27. Dannan GA, Porubek DJ, Nelson SD, Waxman DJ, Guengerich FP. 17 β -estradiol 2- and 4-hydroxylation catalyzed by rat hepatic cytochrome P-450: roles of individual forms, inductive effects, developmental patterns and alterations by gonadectomy and hormone replacement. (1986) Endocrinology **118**, 1952-1960.
28. Park SS, Waxman DJ, Miller H, Robinson R, Attisano C, Guengerich FP, Gelboin HV. Preparation and characterization of monoclonal antibodies to pregnenolone 16 α -carbonitrile-inducible rat hepatic cytochrome P-450. (1986) Biochem Pharmacol **35**, 2859-2867.
29. Waxman DJ. Rat hepatic cholesterol 7 α -hydroxylase: biochemical characterization and comparison to constitutive and xenobiotic-inducible cytochrome P-450 enzymes. (1986) Arch Biochem Biophys **247**, 335-345.

30. Guengerich FP, Martin MV, Beaune PH, Kremers P, Wolff T, Waxman DJ. Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. (1986) J Biol Chem **261**, 5051-5060.
31. Frey AB, Kreibich G, Wadhera A, Clarke L, Waxman DJ. 3-(Trifluoromethyl)-3-(m-[¹²⁵I]iodophenyl)diazirine photolabels a substrate-binding site of rat hepatic cytochrome P-450 form PB-4. (1986) Biochemistry **25**, 4797-4803.
32. Friedberg T, Waxman DJ, Atchison M, Kumar A, Haaparanta T, Raphael C, Adesnik M. Isolation and characterization of cDNA clones for cytochromes P-450 immunochemically related to rat hepatic P-450 form PB-1. (1986) Biochemistry **25**, 7975-7983.
33. Dannan GA, Guengerich FP, Waxman DJ. Hormonal regulation of rat liver microsomal enzymes: role of gonadal steroids in programming, maintenance and suppression of Δ^4 -steroid 5 α -reductase, flavin-containing monooxygenase and sex-specific cytochromes P-450. (1986) J Biol Chem **261**, 10728-10735.
34. McClellan-Green P, Waxman DJ, Caveness M, Goldstein JA. Phenotypic differences in expression of cytochrome P-450g but not its mRNA in outbred male Sprague-Dawley rats. (1987) Arch Biochem Biophys **253**, 13-25.
35. Clarke L, Rosowsky A, Waxman DJ. Inhibition of human liver folylpolyglutamate synthetase by non- γ -glutamylatable folate analogs. (1987) Molec Pharmacol **31**, 122-127.
36. Wright JE, Rosowsky A, Waxman DJ, Trites D, Cucchi CA, Flatow J, Frei E III. Metabolism of methotrexate and γ -tert-butyl-methotrexate by human leukemic cells in culture and by hepatic aldehyde oxidase in vitro. (1987) Biochem Pharmacol **36**, 2209-2214.
37. Holsztynska EJ, Waxman DJ. Cytochrome P-450 cholesterol 7 α -hydroxylase: Inhibition of enzyme deactivation by structurally diverse calmodulin antagonists and phosphatase inhibitors. (1987) Arch Biochem Biophys **256**, 543-559.
38. Clarke L, Waxman DJ. Human Liver folylpolyglutamate synthetase: biochemical characterization and interactions with folates and folate antagonists. (1987) Arch Biochem Biophys **256**, 585-596.
39. Yeowell HN, Waxman DJ, Wadhera A, Goldstein JA. Suppression of the constitutive, male-specific rat hepatic cytochrome P-450 2c and its mRNA by 3,4,5,3',4',5'-hexachlorobiphenyl and 3-methylcholanthrene. (1987) Molec Pharmacol **32**, 340-347.
40. Schwarz M, Peres G, Buchmann A, Friedberg T, Waxman DJ, Kunz W. Phenobarbital induction of cytochrome P-450 in normal and preneoplastic rat liver: comparison of enzyme and mRNA expression as detected by immunohistochemistry and in situ hybridization. (1987) Carcinogenesis **8**, 1355-1357.
41. Steinberg P, Lafranconi WM, Wolf CR, Waxman DJ, Oesch F, Friedberg T. Xenobiotic metabolizing enzymes are not restricted to parenchymal cells in rat liver. (1987) Molec Pharmacol **32**, 463-470.
42. Waxman DJ, Lapenson DP, Park SS, Attisano C, Gelboin HV. Monoclonal antibodies inhibitory to rat hepatic cytochromes P-450: P-450 form specificities and use as probes for cytochrome P-450-dependent steroid hydroxylations. (1987) Molec Pharmacol **32**, 615-624.
43. Yeowell HN, Waxman DJ, LeBlanc GA, Linko P, Goldstein JA. Induction of rat cytochrome P-450 3 and its mRNA by 3,4,5,3',4',5'-hexachlorobiphenyl. (1988) Molec Pharmacol **33**, 272-278.
44. Waxman DJ, Lapenson DP, Krishnan M, Bernard O, Kreibich G, Alvarez F. Antibodies to liver/kidney microsomal in chronic active hepatitis recognize specific forms of hepatic cytochrome P-450. (1988) Gastroenterology **95**, 1326-1331.

45. Waxman DJ, Attisano C, Guengerich FP, Lapenson DP. Human liver microsomal steroid metabolism. Identification of the major microsomal steroid hormone 6 β -hydroxylase cytochrome P-450 enzyme. (1988) Arch Biochem Biophys **263**, 424-436.
46. Waxman DJ, LeBlanc GA, Morrissey JJ, Staunton J, Lapenson DP. Adult male-specific and neonatally programmed rat hepatic P-450 forms RLM2 and 2a are not dependent on pulsatile plasma growth hormone for expression. (1988) J Biol Chem **263**, 11396-11406.
47. LeBlanc GA, Waxman DJ. Feminization of rat hepatic P-450 expression by cisplatin. Evidence for perturbations in the hormonal regulation of steroid-metabolizing enzymes. (1988) J Biol Chem **263**, 15732-15739.
48. Matsunaga T, Nagata K, Holsztynska EJ, Lapenson DP, Smith A, Kato R, Gelboin HV, Waxman DJ, Gonzalez FJ. Gene conversion and differential regulation in the rat P-450 IIA gene subfamily. Purification, catalytic activity, cDNA and deduced amino acid sequence, and regulation of an adult male-specific hepatic testosterone 15 α -hydroxylase. (1988) J Biol Chem **263**, 17995-18002.
49. Oesch F, Waxman DJ, Morrissey JJ, Honscha W, Kissel W, Friedberg T. Antibodies targeted against hypervariable and constant regions of cytochrome P450IIB1 and P450IIB2. (1989) Arch Biochem Biophys **270**, 23-32.
50. Koch JA, Waxman DJ. Post-translational modification of hepatic cytochrome P-450. Phosphorylation of phenobarbital-inducible P-450 forms PB-4 (IIB1) and PB-5 (IIB2) in isolated rat hepatocytes and in vivo. (1989) Biochemistry **28**, 3145-3152.
51. Waxman DJ, Morrissey JJ, LeBlanc GA. Female-predominant rat hepatic cytochrome P-450 forms j (IIE1) and 3 (IIA1) are under hormonal regulatory controls distinct from those of the sex-specific P-450 forms. (1989) Endocrinology **124**, 2954-2966.
52. Clarke L, Waxman DJ. Oxidative metabolism of cyclophosphamide. Identification of the hepatic monooxygenase catalysts of drug activation. (1989) Cancer Research **49**, 2344-2350.
53. Zimniak P, Holsztynska E, Lester R, Waxman DJ, Radomska A. The detoxification of lithocholic acid. Elucidation of the pathways of oxidative metabolism in rat liver microsomes. (1989) Lipid Res **30**, 907-918.
54. Bartlomowicz B, Waxman DJ, Utesch D, Oesch F, Friedberg T. Phosphorylation of carcinogen metabolizing enzymes: Regulation of the phosphorylation status of the major phenobarbital inducible cytochromes P-450 in hepatocytes. (1989) Carcinogenesis **10**, 225-228.
55. Park SS, Waxman DJ, Lapenson DP, Schenkman JB, Gelboin HV. Monoclonal antibodies to rat liver cytochrome P-450 2c/RLM5 that regiospecifically inhibit steroid metabolism. (1989) Biochem Pharmacol **38**, 3067-3074.
56. Waxman DJ, Morrissey JJ, LeBlanc GA. Hypophysectomy differentially alters P-450 protein levels and enzyme activities in rat liver. Pituitary control of hepatic NADPH cytochrome P-450 reductase. (1989) Molec Pharmacol **35**, 519-525.
57. Waxman DJ, Lapenson DP, Morrissey JJ, Park SS, Gelboin HV, Doeheer J, Oesch F. Androgen hydroxylation catalyzed by a cell line (SD1) that stably expresses rat hepatic P-450 PB-4 (IIB1). (1989) Biochem J **260**, 81-85.
58. Yeowell HN, Waxman DJ, LeBlanc GA, Linko P, Goldstein JA. Suppression of male-specific cytochrome P-450 2c and its mRNA by 3,4,5,3',4',5'-hexachlorobiphenyl in rat liver is not causally related to changes in serum testosterone. (1989) Arch Biochem Biophys **271**, 508-514.

59. Aoyama T, Yamano S, Waxman DJ, Lapenson DP, Meyer UA, Fischer V, Tyndale R, Inaba T, Kalow W, Gelboin HV, Gonzalez FJ. Cytochrome P450 hPCN3, a novel P450 IIIA gene product that is differentially expressed in adult human liver: cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. (1989) J Biol Chem **264**, 10388-10395.
60. Teicher BA, Waxman DJ, Holden SA, Wang Y, Clarke L, Sotomayor EA, Jones SM, Frei E III. Evidence for enzymatic activation and oxygen involvement in cytotoxicity and antitumor activity of N,N,N'-triethylenethiophosphoramidate. (1989) Cancer Res **49**, 4996-5001.
61. Shapiro BH, MacLeod JN, Pampori NA, Morrissey JJ, Lapenson DP, Waxman DJ. Signalling elements in the ultradian rhythm of circulating growth hormone regulating expression of sex-dependent forms of hepatic cytochrome P-450. (1989) Endocrinology **125**, 2935-2944.
62. Aoyama T, Korzekwa K, Nagata K, Adesnik M, Reiss A, Lapenson DP, Gillette J, Gelboin HV, Waxman DJ, Gonzalez FJ. Sequence requirements for cytochrome P450 IIB1 catalytic activity. Alteration of the stereospecificity and regioselectivity of steroid hydroxylation by a simultaneous change of two hydrophobic amino acid residues to phenylalanine. (1989) J Biol Chem **264**, 21327-21333.
63. Waxman DJ, Lapenson DP, Nagata K, Conlon HD. Participation of two structurally related enzymes in rat hepatic microsomal androstenedione 7 α -hydroxylation. (1990) Biochem J **265**, 187-194.
64. Waxman DJ, Morrissey JJ, MacLeod JN, Shapiro BH. Depletion of serum growth hormone in adult female rats by neonatal monosodium glutamate without loss of female-specific hepatic enzymes P-450 2d (IIC12) and steroid 5 α -reductase. (1990) Endocrinology **126**, 712-720.
65. Ng S, Waxman DJ. Biotransformation of N,N,N'-triethylenethiophosphoramidate (thio-TEPA): oxidative desulfuration to yield TEPA associated with suicide inactivation of a phenobarbital-inducible hepatic P-450 monooxygenase. (1990) Canc Res **50**, 464-471.
66. Janeczko R, Waxman DJ, LeBlanc GA, Morville A, Adesnik M. Hormonal regulation of levels of the messenger RNA encoding hepatic P-450 2c (IIC11), a constitutive male-specific form of cytochrome P-450. (1990) Molec Endocrinol **4**, 295-303.
67. Waxman DJ, Ram PA, Notani G, LeBlanc GA, Alberta JA, Morrissey JJ, Sundseth SS. Pituitary regulation of male-specific steroid 6 β -hydroxylase P-450 2a (gene product IIIA2) in adult rat liver. Suppressive influence of growth hormone and thyroxine acting at a pretranslational level. (1990) Molec Endocrinol **4**, 447-454.
68. Rosowsky A, Wright JE, Holden SA, Waxman DJ. Influence of lipophilicity and carboxyl group content on the rate of hydroxylation of methotrexate derivatives by aldehyde oxidase. (1990) Biochem Pharmacol **40**, 851-857.
69. LeBlanc GA, Waxman DJ. Mechanisms of cyclophosphamide action on hepatic P450 expression. (1990) Canc Res **50**, 5720-5726.
70. Waxman DJ, Morrissey JJ, Naik S, Jauregui HO. Phenobarbital induction of cytochromes P-450. High level, long-term responsiveness of primary rat hepatocyte cultures to drug inducers and glucocorticoid dependence of the phenobarbital response. (1990) Biochem J **271**, 113-119.
71. LeBlanc GA, Waxman DJ. Regulation and ligand-binding specificities of two sex-specific bile acid binding proteins of rat liver cytosol. (1990) J Biol Chem **265**, 5654-5661.

72. Falck JR, Lumin S, Blair I, Dishman E, Martin MV, Waxman DJ, Guengerich FP, Capdevila JH. Cytochrome P-450-dependent oxidation of arachidonic acid to 16-, 17-, and 18-hydroxyeicosatetraenoic acids. (1990) J Biol Chem **265**, 10244-10249.
73. Capdevila JH, Karara A, Waxman DJ, Martin MV, Falck JR, Guengerich FP. Cytochrome P-450 enzyme-specific control of the regio- and enantiofacial selectivity of the microsomal arachidonic acid epoxigenase. (1990) J Biol Chem **265**, 10865-10871.
74. Sundseth SS, Waxman DJ. Hepatic P-450 cholesterol 7 α -hydroxylase. Regulation in vivo at the protein and mRNA level in response to mevalonate, diurnal rhythm and bile acid feedback. (1990) J Biol Chem **265**, 15090-15095.
75. Ram PA, Waxman DJ. Pretranslational control by thyroid hormone of rat liver steroid 5 α -reductase and comparison to the thyroid dependence of two growth hormone-regulated CYP2C mRNAs. (1990) J Biol Chem **265**, 19223-19229.
76. Jauregui HO, Ng S, Gann K, Waxman DJ. Xenobiotic induction of P-450 PB-4 (IIB1) and P-450c (IA1) and associated monooxygenase activities in primary cultures of adult rat hepatocytes. (1991) Xenobiotica **21**, 1091-1106.
77. Ram PA, Waxman DJ. Hepatic P450 expression in hypothyroid rats: Differential responsiveness of male-specific P450 forms 2a (IIIA2), 2c (IIC11), and RLM2 (IIA2) to thyroid hormone. (1991) Molec Endocrinol **5**, 13-20.
78. Pampori NA, Agrawal AK, Waxman DJ, Shapiro BH. Differential effects of neonatally administered glutamate on the ultradian pattern of circulating growth hormone regulating expression of sex-dependent forms of cytochrome P450. (1991) Biochem Pharmacol **41**, 1299-1309.
79. Zimniak P, Holsztynska EJ, Radomska A, Iscan M, Lester R, Waxman DJ. Distinct forms of cytochrome P450 are responsible for 6 β -hydroxylation of bile acids and of neutral steroids. (1991) Biochem J **275**, 105-111.
80. Nebert DW, Nelson DR, Coon MJ, Estabrook RW, Feyereisen R, Fujii-Kuriyama Y, Gonzalez FJ, Guengerich FP, Gunsalus IC, Johnson EF, Loper JC, Sato R, Waterman MR, Waxman DJ. The P450 superfamily: Update on new sequences, gene mapping, and recommended nomenclature. (1991) DNA Cell Biol **10**, 1-14, and (1991) DNA Cell Biol **10**, 397-398 (addendum).
81. Ng S, Waxman DJ. N,N',N"-Triethylenethiophosphoramidate (Thio-TEPA) oxygenation by constitutive hepatic P450 enzymes and modulation of drug metabolism and clearance in vivo by P450 inducing agents. (1991) Canc Res **51**, 2340-2345.
82. Waxman DJ, Lapenson DP, Aoyama T, Gelboin HV, Gonzalez FJ, Korzekwa K. Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s. (1991) Arch Biochem Biophys **290**, 160-166.
83. Waxman DJ, Pampori NA, Ram PA, Agrawal AK, Shapiro BH. Interpulse interval in circulating growth hormone patterns regulates sexually dimorphic expression of hepatic cytochrome P450. (1991) Proc Natl Acad Sci USA **88**, 6868-6872.
84. Ram PA, Waxman DJ. Thyroid hormone stimulation of NADPH P450 reductase expression in liver and extrahepatic tissues. Regulation by multiple mechanisms. (1992) J Biol Chem **267**, 3294-3301.
85. LeBlanc GA, Kantoff PW, Ng S, Frei E III, Waxman DJ. Hormonal perturbations in patients with testicular cancer treated with cisplatin. (1992) Cancer **69**, 2306-2310.

86. LeBlanc GA, Sundseth SS, Weber GF, Waxman DJ. Platinum anticancer drugs modulate P450 mRNA levels and differentially alter hepatic drug and steroid hormone metabolism in male and female rats. (1992) Canc Res **52**, 540-547.
87. Sundseth SS, Alberta JA, Waxman DJ. Sex-specific, growth hormone-regulated transcription of the cytochrome P450 2C11 and 2C12 genes. (1992) J Biol Chem **267**, 3907-3914.
88. Sundseth SS, Waxman DJ. Sex-dependent expression and clofibrate inducibility of cytochrome P450 fatty acid ω -hydroxylases. Male-specificity of liver and kidney CYP4A2 mRNA and tissue-specific regulation by growth hormone and testosterone. (1992) J Biol Chem **267**, 3915-3921.
89. Correia MA, Yao K, Wrighton SA, Waxman DJ, Rettie AE. Differential apoprotein loss of rat liver cytochromes P450 after their inactivation by 3,5-dicarboethoxy-2,6-dimethyl-4-ethyl-1,4-dihydropyridine: a case for distinct proteolytic mechanisms? (1992) Arch Biochem Biophys **294**, 493-503.
90. Park SS, Walker W, Aoyama T, Lapenson DP, Waxman DJ, Gonzalez FJ, Gelboin HV. Monoclonal antibodies to rat liver microsomal cytochrome b5. (1992) Biochem Pharmacol **43**, 2201-2208.
91. Waxman DJ, Sundseth SS, Srivastava PK, Lapenson DP. Gene-specific oligonucleotide probes for alpha, mu, pi and microsomal rat glutathione S-transferases: Analysis of liver transferase expression and its modulation by hepatic enzyme inducers and platinum anticancer drugs. (1992) Canc Res **52**, 5797-5802.
92. Chang TKH, Teixeira J, Gil G, Waxman DJ. The lithocholic acid 6 β -hydroxylase cytochrome P450, CYP 3A10, is an active catalyst of steroid hormone 6 β -hydroxylation. (1993) Biochem J **291**, 429-434.
93. Weber G, Waxman DJ. Activation of the anti-cancer drug ifosphamide by rat liver microsomal P450 enzymes. (1993) Biochem Pharmacol **45**, 1685-1694.
94. Shapiro BH, Pampori NA, Ram PA, Waxman DJ. Irreversible suppression of growth hormone-dependent cytochrome P450 2C11 in adult rats neonatally treated with monosodium glutamate. (1993) J Pharm Exp Ther **265**, 979-984.
95. Nanji AA, Zhao S, Lamb RG, Sadrzadeh SMH, Dannenberg AJ, Waxman DJ. Changes in microsomal phospholipases and arachidonic acid in experimental alcoholic liver injury: relationship to cytochrome P-450 2E1 induction and conjugated diene formation. (1993) Alcohol Clin Exp Res **17**, 598-603.
96. Ng S, Waxman DJ. Activation of thio-TEPA cytotoxicity toward human breast cancer cells by hepatic cytochrome P450. (1993) Int J Oncology **2**, 731-738.
97. Nelson DR, Kamataki T, Waxman DJ, Guengerich FP, Estabrook RW, Feyereisen R, Gonzalez FJ, Coon MJ, Gunsalus IC, Gotoh O, Okuda K, Nebert DW. The P450 superfamily: Update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. (1993) DNA Cell Biol **12**, 1-52.
98. Srivastava PK, Waxman DJ. Sex-dependent expression and growth hormone regulation of class alpha and class mu glutathione S-transferase mRNAs in adult rat liver. (1993) Biochem J **294**, 159-165.
99. Chang TKH, Waxman DJ. Cyclophosphamide modulates rat hepatic cytochrome P450 2C11 and steroid 5 α -reductase activity and mRNA levels through the combined action of acrolein and phosphoramidate mustard. (1993) Canc Res **53**, 2490-2497.
100. Frei E III, Holden SA, Gonin R, Waxman DJ, Teicher BA. Antitumor alkylating agents: In vitro cross-resistance and collateral sensitivity studies. (1993) Canc Chemother Pharmacol **33**, 113-122.

101. Weber GF, Waxman DJ. Denitrosation of the anti-cancer drug BCNU catalyzed by microsomal glutathione S-transferase and cytochrome P450 monooxygenases. (1993) Arch Biochem Biophys **307**, 369-378.
102. Chang TKH, Weber GF, Crespi CL, Waxman DJ. Differential activation of cyclophosphamide and ifosfamide by cytochromes P450 2B and 3A in human liver microsomes. (1993) Canc Res **53**, 5629-5637.
103. Chen G, Waxman DJ. Role of cellular glutathione and glutathione S-transferase in the expression of alkylating agent cytotoxicity in human breast cancer cells. (1994) Biochem Pharmacol **47**, 1079-1087.
104. Nanji AA, Zhao S, Sadrzadeh SMH, Khettry U, Waxman DJ. Cimetidine prevents alcoholic hepatic injury in the intragastric feeding rat model. (1994) J Pharm Exp Therap **269**, 832-837.
105. Nanji AA, Zhao S, Lamb RG, Dannenberg AJ, Sadrzadeh SMH, Waxman DJ. Changes in cytochromes P-450 2E1, 2B1, and 4A, and phospholipases A and C in the intragastric feeding rat model for alcoholic liver disease: relationship to dietary fats and pathological liver injury. (1994) Alcohol Clin Exp Res **18**, 902-908.
106. Nanji AA, Zhao S, Sadrzadeh SMH, Waxman DJ. Use of reverse transcriptase-polymerase chain reaction to evaluate in vivo cytokine gene expression in rats fed ethanol for long periods. (1994) Hepatology **19**, 1483-1487.
107. Shapiro BH, Pampori NA, Lapenson DP, Waxman DJ. Growth hormone-dependent and -independent sexually dimorphic regulation of phenobarbital-induced hepatic cytochromes P450 2B1 and 2B2. (1994) Arch Biochem Biophys **312**, 234-239.
108. Ram PA, Waxman DJ. Dehydroepiandrosterone 3 β -sulfate is an endogenous activator of the peroxisome proliferator pathway. Induction of cytochrome P450 4A and acyl CoA-oxidase mRNAs in primary rat hepatocytes and inhibitory effects of Ca²⁺ channel blockers. (1994) Biochem J **301**, 753-758.
109. Prough RA, Webb SJ, Wu HQ, Lapenson DP, Waxman DJ. Induction of microsomal and peroxisomal enzymes by dehydroepiandrosterone and its reduced metabolite in rats. (1994) Canc Res **54**, 2878-2886.
110. Lee YH, Alberta JA, Gonzalez FJ, Waxman DJ. Multiple, functional DBP sites on the promoter of the cholesterol 7 α -hydroxylase P450 gene, CYP7. Proposed role in diurnal regulation of liver gene expression. (1994) J Biol Chem **269**, 14681-14689.
111. Chang TKH, Gonzalez FJ, Waxman DJ. Evaluation of triacetyloleandomycin, α -naphthoflavone and diethylthiocarbamate as selective chemical probes for inhibition of human cytochromes P450. (1994) Arch Biochem Biophys **311**, 437-442.
112. Wei MX, Tamiya T, Chase M, Boviatsis EJ, Chang TKH, Kowall NA, Hochberg FH, Waxman DJ, Breakefield XO, Chiocca EA. Experimental tumor therapy using the cyclophosphamide-activating cytochrome P450 2B1 gene. (1994) Human Gene Therapy **5**, 969-978.
113. Chang TKH, Chen H, Waxman DJ. 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) modulates rat liver microsomal cyclophosphamide and ifosfamide activation by suppressing cytochrome P450 2C11 messenger RNA levels. (1994) Drug Metab Dispos **22**, 673-679.
114. Jean A, Reiss A, Desrochers M, Dubois S, Trottier E, Trottier Y, Wirtanen L, Adesnik M, Waxman DJ, Anderson A. Rat liver cytochrome P450 2B3: Structure of CYP2B3 gene and immunological identification of a constitutive P450 2B3-like protein in rat liver. (1994) DNA Cell Biol **13**, 781-792.
115. Nanji AA, Zhao S, Sadrzadeh SMH, Dannenberg AJ, Tahan SR, Waxman DJ. Markedly enhanced cytochrome P450 2E1 induction and lipid peroxidation is associated with severe liver injury in fish oil-ethanol fed rats. (1994) Alcohol Clin Exp Res **18**, 1280-1285.

116. Chen L, Waxman DJ. Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy. (1995) Canc Res **55**, 581-589.
117. Chen G, Waxman DJ. Identification of glutathione S-transferase as a determinant of 4-hydroperoxycyclophosphamide resistance in human breast cancer cells. (1995) Biochem Pharmacol **49**, 1691-1701.
118. Chang TKH, Chen G, Waxman DJ. Modulation of thio-TEPA anti-tumor activity in vivo by alteration of liver cytochrome P450-catalyzed drug metabolism. (1995) J Pharm Exp Therap **274**, 270-275.
119. Waxman DJ, Ram PA, Park S-H, Choi HK. Intermittent plasma growth hormone triggers tyrosine phosphorylation and nuclear translocation of a liver-expressed, Stat 5-related DNA-binding protein. Proposed role as an intracellular regulator of male-specific liver gene transcription. (1995) J Biol Chem **270**, 13262-13270.
120. Rifkind AB, Lee C, Chang TKH, Waxman DJ. Arachidonic acid metabolism by human cytochrome P450s 2C8, 2C9, 2E1 and 1A2: regioselective oxygenation and evidence for a role for CYP2C enzymes in arachidonic acid epoxidation in human liver microsomes. (1995) Arch Biochem Biophys **320**, 380-389.
121. Chen G, Waxman DJ. Complete reversal by thalibastine of 490-fold Adriamycin resistance in multidrug resistant (MDR) human breast cancer cells: evidence that multiple biochemical changes in MDR cells do not necessarily indicate multiple determinants for drug resistance. (1995) J Pharm Exp Therap **274**, 1271-1277.
122. Waxman DJ, Ram PA, Pampori NA, Shapiro BH. Growth hormone regulation of male-specific rat liver P450s 2A2 and 3A2. Induction by intermittent growth hormone pulses in male but not female rats rendered growth hormone deficient by neonatal monosodium glutamate. (1995) Molec Pharmacol **48**, 790-797.
123. Chen L, Waxman DJ, Chen D, Kufe D. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene. (1996) Canc Res **56**, 1331-1340.
124. Ram PA, Park S-H, Choi HK, Waxman DJ. Growth hormone activation of Stat 1, Stat 3 and Stat 5 in rat liver. Differential kinetics of hormone desensitization and growth hormone stimulation of both tyrosine phosphorylation and serine/threonine phosphorylation. (1996) J Biol Chem **271**, 5929-5940.
125. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, Gunsalus IC, Nebert DW. Cytochrome P450 superfamily: Update on new sequences, gene mapping, accession numbers, and nomenclature. (1996) Pharmacogenetics **6**, 1-42.
126. Peters JM, Zhou YC, Ram PA, Lee SST, Gonzalez FJ, Waxman DJ. Peroxisome proliferator-activated receptor α required for gene induction by dehydroepiandrosterone β -sulfate. (1996) Molec Pharmacol **50**, 67-74.
127. Yu L, Waxman DJ. Role of cytochrome P450 in oxazaphosphorine metabolism: Deactivation via N-dechloroethylation and activation via 4-hydroxylation catalyzed by distinct subsets of rat liver cytochromes P450. (1996) Drug Metab Dispos **24**, 1254-1262.
128. Yi W, Kim SO, Jiang J, Park SH, Kraft AS, Waxman DJ, Frank SJ. Growth hormone receptor cytoplasmic domain differentially promotes tyrosine phosphorylation of signal transducers and activators of transcription 5b and 3 by activated JAK2 kinase. (1996) Molec Endocrinol **10**, 1425-1443.
129. Waxman DJ, Zhao S, Choi HK. Interaction of a novel sex-dependent, growth hormone-regulated nuclear factor with CYP2C12 promoter. (1996) J Biol Chem **271**, 29978-29987.

130. Chang TKH, Yu L, Goldstein JA, Waxman DJ. Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-Ile³⁵⁹ allele as low-K_m catalysts of cyclophosphamide and ifosfamide activation. (1997) Pharmacogenetics **7**, 211-221.
131. Code EL, Crespi CL, Penman BW, Gonzalez FJ, Chang TKH, Waxman DJ. Human cytochrome P4502B6. Interindividual hepatic expression, substrate specificity, and role in procarcinogen activation. (1997) Drug Metab Dispos **29**, 985-993.
132. Gebert CA, Park SH, Waxman DJ. Regulation of signal transducer and activator of transcription (STAT) 5b activation by the temporal pattern of growth hormone stimulation. (1997) Molec Endocrinol **11**, 400-414.
133. Udy GB, Towers RP, Snell RG, Wilkins RJ, Park SH, Ram PA, Waxman DJ, Davey HW. Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression. (1997) Proc Natl Acad Sci USA **94**, 7239-7244.
134. O'Leary KA, Li H-C, Ram PA, McQuiddy P, Waxman DJ, Kasper CB. Thyroid regulation of NADPH:cytochrome P450 oxidoreductase: Identification of a thyroid-responsive element in the 5'-flank of the oxidoreductase gene. (1997) Molec Pharmacol **52**, 46-53.
135. Chang TKH, Yu L, Maurel P, Waxman DJ. Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: Response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. (1997) Cancer Res **57**, 1946-1954.
136. Ram PA, Waxman DJ. Interaction of growth hormone-activated STATs with SH2-containing phosphotyrosine phosphatase SHP-1 and nuclear JAK2 tyrosine kinase. (1997) J Biol Chem **272**, 17694-17702.
137. Chen L, Yu LJ, Waxman DJ. Potentiation of cytochrome P450/cyclophosphamide-based cancer gene therapy by transfer of the P450 reductase gene. (1997) Cancer Res **57**, 4830-4837.
138. Brain EGC, Yu LJ, Gustafsson K, Drewes P, Waxman DJ. Modulation of P450-dependent ifosfamide pharmacokinetics: A better understanding of drug activation *in vivo*. (1998) Br J Cancer **77**, 1768-1776.
139. Zhou YC, Waxman DJ. Activation of peroxisome proliferator-activated receptors by chlorinated hydrocarbons and endogenous steroids. (1998) Environ Health Perspect **106**, 983-988.
140. Jounaidi Y, Hecht JED, Waxman DJ. Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy. (1998) Canc Res **58**, 4391-4401.
141. Gebert CA, Park SH, Waxman DJ. Termination of growth hormone pulse-induced STAT5b signaling. (1999) Molec Endocrinol **13**, 38-56.
142. Yu LJ, Drewes P, Gustafsson K, Brain EGC, Hecht JED, Waxman DJ. In vivo modulation of alternative pathways of P450-catalyzed cyclophosphamide metabolism: impact on pharmacokinetics and antitumor activity. (1999) J Pharm Exp Ther **288**, 928-937.
143. Gebert CA, Park SH, Waxman DJ. Down-regulation of liver JAK2-STAT5b signaling by the female plasma pattern of continuous growth hormone stimulation. (1999) Molec Endocrinol **13**, 213-227.
144. Zhou YC, Waxman DJ. Cross-talk between Janus kinase signal transducer and activator of transcription (JAK-STAT) and peroxisome proliferator-activated receptor- α (PPAR α) signaling pathways. Growth hormone inhibition of PPAR α transcriptional activity mediated by STAT5b. (1999) J Biol Chem **274**, 2672-2681.

145. Park SH, Liu X, Hennighausen L, Davey HW, Waxman DJ. Distinctive roles of STAT5a and STAT5b in sexual dimorphism of hepatic P450 gene expression. Impact of *Stat5a* gene disruption. (1999) *J Biol Chem* 274, 7421-7430.
146. Roy P, Yu L, Crespi CL, Waxman DJ. Development of a substrate-activity based approach to identify the major human liver P450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P450 profiles. (1999) *Drug Metab Dispos* 27, 655-666.
147. Huang Z, Waxman DJ. HPLC-Fluorescent method to determine chloroacetaldehyde, a neurotoxic metabolite of the anti-cancer drug ifosfamide, in plasma and in liver microsomal incubations. (1999) *Analyt Biochem* 273, 117-125.
148. Roy P, Tretyakov O, Wright J, Waxman DJ. Stereoselective metabolism of ifosfamide by human P450s 3A4 and 2B6. Favorable metabolic properties of *R*-enantiomer. (1999) *Drug Metab Dispos* 27, 1309-1318.
149. Choi HK, Waxman DJ. Growth hormone, but not prolactin, maintains low-level activation of STAT5a and STAT5b in female rat liver. (1999) *Endocrinology* 140, 5126-5135.
150. Zhou YC, Waxman DJ. STAT5b down-regulates transcription by inhibition of ligand-independent activation function region-1 *trans*-activation domain. (1999) *J Biol Chem* 274, 29874-29882.
151. Maloney EK, Waxman DJ. *trans*-Activation of PPAR α and PPAR γ by structurally diverse environmental chemicals. (1999) *Toxicol Appl Pharmacol* 161, 209-218.
152. Davey HW, Park SH, Grattan DR, McLachlan MJ, Waxman DJ. STAT5b-deficient mice are growth hormone pulse-resistant. Role of STAT5b in sex-specific liver P450 expression. (1999) *J Biol Chem* 274, 35331-35336.
153. Ram PA, Waxman DJ. SOCS/CIS protein inhibition of growth hormone-stimulated STAT5 signaling by multiple mechanisms. (1999) *J Biol Chem* 274, 35553-35561.
154. Huang Z, Raychowdhury, MK, Waxman DJ. Impact of liver P450 reductase suppression on cyclophosphamide activation, pharmacokinetics and antitumor activity in a cytochrome P450-based cancer gene therapy model. (2000) *Cancer Gene Therapy* 7, 1034-1042.
155. Huang Z, Roy P, Waxman DJ. Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. (2000) *Biochem Pharmacol* 59, 961-972.
156. Jounaïdi Y, Waxman DJ. Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy. (2000) *Canc Res* 60, 3761-3769.
157. Choi HK, Waxman DJ. Plasma growth hormone pulse activation of hepatic JAK-STAT5 signaling: developmental regulation and role in male-specific liver gene expression. (2000) *Endocrinology* 141, 3245-3255.
158. Delesque-Touchard N, Park SH, Waxman DJ. Synergistic action of hepatocyte nuclear factors 3 and 6 on *CYP2C12* gene expression and down-regulation by growth hormone-activated STAT5b. Proposed model for female-specific expression of *CYP2C12* in adult rat liver. (2000) *J Biol Chem* 275, 34173-34182.
159. Ram PA, Waxman DJ. Role of the cytokine-inducible SH2 protein CIS in desensitization of STAT5b signaling by continuous GH. (2000) *J Biol Chem* 275, 39487-39496.
160. Dillon JS, Yaney GC, Zhou Y, Voilley N, Bowen S, Chipkin S, Bliss CR, Schultz V, Schuit FC, Prentki M, Waxman DJ, Corkey BE. Dehydroepiandrosterone sulfate and β -cell function: Enhanced glucose-

- induced insulin secretion and altered gene expression in rodent pancreatic β -cells. (2000) Diabetes **49**, 2012-2020.
161. Yu LJ, Matias J, Scudiero DA, Hite KM, Monks A, Sausville EA, Waxman DJ. P450 enzyme expression patterns in the NCI human tumor cell line panel. (2001) Drug Metab Dispos **29**, 304-312.
162. Li HC, Liu D, Waxman DJ. Transcriptional induction of hepatic NADPH: cytochrome P450 oxidoreductase by thyroid hormone. (2001) Molec Pharmacol **59**, 987-995.
163. Davey HW, Xie T, McLachlan MJ, Wilkins RJ, Waxman DJ, Grattan DR. STAT5b is required for GH-induced liver Igf-I gene expression. (2001) Endocrinology **142**, 3835-3841.
164. Huang Z, Waxman DJ. Modulation of cyclophosphamide-based cytochrome P450 gene therapy using liver P450 inhibitors. (2001) Cancer Gene Therapy **8**, 450-458.
165. Jounaidi Y, Waxman DJ. Frequent, moderate dose cyclophosphamide administration improves the efficacy of P450/P450-reductase-based cancer gene therapy. (2001) Canc Res **61**, 4437-4444.
166. Xie W, Radomska-Pandya A, Shi Y, Simon CM, Nelson MC, Ong ES, Waxman DJ, Evans RM. An essential role for SXR/PXR in detoxification of cholestatic bile acids. (2001) Proc Natl Acad Sci USA **98**, 3375-3380.
167. Park SH, Yamashita H, Rui H, Waxman DJ. Serine phosphorylation of GH-activated STAT5a and STAT5b: impact on STAT5 transcriptional activity. (2001) Molec Endocrinol **15**, 2157-2171.
168. Tannenbaum GS, Choi HK, Gurd W, Waxman DJ. Temporal relationship between the sexually dimorphic spontaneous GH secretory profiles and hepatic STAT5 activity. (2001) Endocrinology **142**, 4599-4606.
169. Park SH, Waxman DJ. Inhibitory cross-talk between STAT5b and liver nuclear factor HNF3 β . Impact on the regulation of growth hormone pulse-stimulated, male specific liver cytochrome P450 gene expression. (2001) J Biol Chem **276**, 43031-43039.
170. Schwartz PS, Waxman DJ. Cyclophosphamide induces caspase 9-dependent apoptosis in 9L tumor cells. (2001) Molec Pharmacol **60**, 1268-1279.
171. Liu D, Waxman DJ. Post-transcriptional regulation of hepatic NADPH- P450 reductase by thyroid hormone: independent effects on poly(A) tail length and mRNA stability (2002) Molec Pharmacol **61**, 1089-1096.
172. Zhou YC, Davey HW, McLachlan MJ, Waxman DJ. Elevated basal expression of liver peroxisomal β -oxidation enzymes and CYP4A microsomal fatty acid ω -hydroxylase in STAT5b^{-/-} mice. Cross-talk in vivo between PPAR and STAT signaling pathways. (2002) Toxicol Applied Pharmacol **182**, 1-10.
173. Tzanakakis ES, Waxman DJ, Hansen LK, Rimmel RP, Hu WS. Long-term enhancement of cytochrome P450 2B1/2 expression in rat hepatocyte spheroids through adenovirus-mediated gene transfer. (2002) Cell Biol Toxicol **18**, 13-27.
174. Schwartz PS, Chen CS, Waxman DJ. Enhanced bystander cytotoxicity of P450 gene-directed enzyme prodrug therapy by expression of the antiapoptotic factor p35. (2002) Canc Res **62**, 6928-6937.
175. Apletalina EV, Li HC, Waxman DJ. Evaluation of thyroid hormone effects on liver P450 reductase translation. (2003) Arch Biochem Biophys **409**, 172-179.
176. Baldwin A, Huang Z, Jounaidi Y, Waxman DJ. Identification of novel enzyme-prodrug combinations for use in cytochrome P450-based gene therapy for cancer. (2003) Arch Biochem Biophys **409**, 197-206.

177. Hurst CH, Waxman DJ. Activation of PPAR α and PPAR γ by environmental phthalate monoesters. (2003) Toxicol Sci **74**, 297-308.
178. Schwartz PS, Chen CS, Waxman DJ. Sustained P450 expression and prodrug activation in bolus cyclophosphamide-treated cultured tumor cells. Impact of prodrug schedule on P450 gene-directed enzyme prodrug therapy. (2003) Cancer Gene Therapy **10**, 571-582.
179. Shipley JM, Waxman DJ. Down-regulation of STAT5b transcriptional activity by ligand-activated PPAR α and PPAR γ . (2003) Molec Pharmacol **64**, 1-10.
180. Ahluwalia A, Clodfelter KH, Waxman DJ. Sexual dimorphism of rat liver gene expression: regulatory role of growth hormone revealed by DNA microarray analysis. (2004) Molec Endocrinol **18**, 747-760.
181. Jounaidi Y, Waxman DJ. Use of replication-conditional adenovirus as a helper system to enhance delivery of P450 prodrug-activation genes for cancer therapy. (2004) Canc Res **64**, 292-303.
182. Su T, Waxman DJ. Impact of dimethyl sulphoxide on expression of nuclear receptors and drug-inducible cytochromes P450 in primary rat hepatocytes. (2004) Arch Biochem Biophys **424**, 226-234.
183. Chen CS, Lin JT, Goss KA, He Y, Halpert JR, Waxman DJ. Activation of the anti-cancer prodrugs cyclophosphamide and ifosfamide. Identification of P450 2B enzymes and site-specific mutants with improved enzyme kinetics. (2004) Molec Pharmacol **65**, 1278-1285.
184. Shipley JM, Hurst CH, Tanaka SS, DeRoos FL, Butenhoff JL, Seacat AM, Waxman DJ. Trans-activation of PPAR α and induction of PPAR α target genes by perfluorooctane-based chemicals. (2004) Toxicol Sci **80**, 151-160.
185. Wiwi CA, Gupte M, Waxman DJ. Sexually dimorphic P450 gene expression in liver-specific hepatocyte nuclear factor 4 α -deficient mice. (2004) Molec Endocrinol **18**, 1975-1987.
186. Schlezinger JJ, Howard GJ, Hurst CH, Emberley JK, Waxman DJ, Webster T, Sherr DH. Environmental and endogenous PPAR γ agonists induce bone marrow B cell growth arrest and apoptosis: interactions between mono-(2-ethylhexyl) phthalate, 9-*cis*-retinoic acid, and 15-deoxy- Δ -prostaglandin J2. (2004) J Immunol **173**, 3165-3177.
187. Hurst CH, Waxman DJ. Environmental phthalate monoesters activate pregnane X receptor-mediated transcription. (2004) Toxicol Appl Pharmacol **199**, 266-274.
188. Shipley JM, Waxman DJ. Simultaneous, bi-directional inhibitory cross-talk between PPAR and STAT5b. (2004) Toxicol Appl Pharmacol **199**, 275-284.
189. Laz EV, Wiwi CA, Waxman DJ. Sexual dimorphism of rat liver nuclear proteins: regulatory role of growth hormone. (2004) Molec Cell Proteomics **3**, 1170-1180.
190. Lu H, Waxman DJ. Anti-tumor activity of methoxymorpholinyl doxorubicin: potentiation by cytochrome P450 3A metabolism. (2005) Molec Pharmacol **67**, 212-219.
191. Wiwi CA, Waxman DH. Role of hepatocyte nuclear factors in transcriptional regulation of male-specific CYP2A2. (2005) J Biol Chem **280**, 3259-3268.
192. Sheu SH, Kaya T, Waxman DJ, Vajda S. Exploring the binding site structure of the PPAR γ ligand-binding domain by computational solvent mapping. (2005) Biochemistry **44**, 1193-1209.

193. Kumar S, Chen CS, Waxman DJ, Halpert JR. Directed evolution of mammalian cytochrome P450 2B1: mutations outside of the active site enhance the metabolism of several substrates including the anticancer prodrugs cyclophosphamide and ifosfamide. (2005) *J Biol Chem* 280, 19569-19575.
194. Chen CS, Jounaidi Y, Waxman DJ. Enantioselective metabolism and cytotoxicity of R-ifosfamide and S-ifosfamide by tumor cell-expressed cytochromes P450. (2005) *Drug Metab Dispos* 33, 1261-1267.
195. Landsman T and Waxman DJ. Role of the cytokine-induced SH2-containing protein CIS in growth hormone receptor internalization. (2005) *J Biol Chem* 280, 37471-37480.
196. Shipley JM, Waxman DJ. Aryl hydrocarbon receptor-independent activation of estrogen receptor-dependent transcription by 3-methylcholanthrene. (2006) *Toxicol Appl Pharmacol* 213, 87-97.
197. Holloway MG, Laz EV, Waxman DJ. Co-dependence of GH-responsive, sexually dimorphic hepatic gene expression on STAT5b and HNF4 α . (2006) *Molec Endocrinol* 20, 647-660.
198. Cheung C, Yu A-M, Chen CS, Krausz KW, Byrd L, Feigenbaum L, Edwards RJ, Waxman DJ, Gonzalez FJ. Growth hormone determines sexual dimorphism of human P450 3A4 expression in transgenic mice. (2006) *J Pharmacol Exp Ther* 316, 1328-1334.
199. Clodfelter KH, Holloway MG, Hodor P, Park SH, Ray WJ, Waxman DJ. Sex-dependent liver gene expression is extensive and largely dependent upon STAT5b: STAT5b-dependent activation of male genes and repression of female genes revealed by microarray analysis. (2006) *Molec Endocrinol* 20, 1333-1351.
200. Jounaidi Y, Chen CS, Veal GJ, Waxman DJ. Enhanced anti-tumor activity of P450 prodrug-based gene therapy using the low Km cyclophosphamide 4-hydroxylase P450 2B11. (2006) *Molec Cancer Therap* 5, 541-555.
201. Gunther M, Waxman DJ, Wagner E, Ogris M. Effects of hypoxia and limited diffusion in tumor cell microenvironment on bystander effect of P450 prodrug therapy. (2006) *Cancer Gene Therapy* 13, 771-779.
202. Park SH, Wiwi CA, Waxman DJ. Signaling cross-talk between hepatocyte nuclear factor 4 α and growth hormone-activated STAT5b. (2006) *Biochem J* 397, 159-168.
203. Clodfelter KH, Waxman DJ, Vajda S. Computational solvent mapping reveals the importance of local conformational changes for broad substrate specificity in mammalian cytochromes P450. (2006) *Biochemistry* 45, 9393-9407.
204. Kaya T, Mohr SC, Waxman DJ, Vajda S. Computational screening of phthalate monoesters for binding to PPAR γ . (2006) *Chem Res Toxicol* 19, 999-1009.
205. Ma X, Idle JR, Malfatti MA, Krausz KW, Nebert DW, Chen CS, Felton JS, Waxman DJ, Gonzalez FJ. Mouse lung CYP1A1 catalyzes the metabolic activation of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). (2007) *Carcinogenesis* 28, 732-737.
206. Holloway MG, Cui Y, Laz EV, Hosui A, Hennighausen L, Waxman DJ. Loss of sexually dimorphic liver gene expression upon hepatocyte-specific deletion of Stat5a-Stat5b locus. (2007) *Endocrinology* 148, 1977-1986.
207. Laz EV, Holloway MG, Chen CS, Waxman DJ. Characterization of three GH-responsive transcription factors preferentially expressed in adult female liver. (2007) *Endocrinology* 207, 1977-1986.
208. Gu J, Chen CS, Wei Y, Fang C, Xie F, Kannan K, Yang W, Waxman DJ, Ding X. A mouse model with liver-specific deletion and global suppression of the NADPH-cytochrome P450 reductase gene:

characterization and utility for in vivo studies of cyclophosphamide disposition. (2007) J Pharm Exp Therap 321, 9-17.

209. Sun L, Chen CS, Waxman DJ, Liu H, Halpert JR, Kumar S. Re-engineering cytochrome P450 2B11dH for enhanced metabolism of several substrates including the anti-cancer prodrugs cyclophosphamide and ifosfamide. (2007) Arch Biochem Biophys 458, 167-174.
210. Clodfelter KH, Miles GD, Wauthier V, Holloway MG, Zhang X, Hodor P, Ray WJ, Waxman DJ. Role of STAT5a in regulation of sex-specific gene expression in female but not male mouse liver revealed by microarray analysis. (2007) Physiol Genomics, in press.
211. Chen CS, Jounaidi Y, Su T, Waxman DJ. Enhancement of intratumoral cyclophosphamide pharmacokinetics and anti-tumor activity in a P450 2B11-based cancer gene therapy model. (2007) Cancer Gene Ther, in press.
212. Ma J, Waxman DJ. Collaboration between hepatic and intratumoral prodrug activation in a P450 prodrug-activation gene therapy model for cancer treatment. (2007) Molec Cancer Therap, submitted.
213. Wiwi CA, Waxman DJ. Growth hormone regulates rat liver hepatocyte nuclear factor 4 α in a sex-dependent manner, in preparation.
214. Johnston TP, Waxman DJ. Poloxamer 407 (P-407) neither modulates PPAR γ activity *in vitro*, nor perturbs plasma insulin and blood glucose concentrations following administration to mice, in preparation.
215. Johnston TP, Waxman DJ. The induction of atherogenic dyslipidemia in poloxamer 407-treated mice is not mediated by PPAR α , in preparation.
216. Ma J, Waxman DJ. Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib. (2007) submitted for publication.

(II) PATENTS and PATENT APPLICATIONS

1. Chiocca EA, Waxman DJ, Wei MX, Breakefield XO, Chen L. Method of selectively destroying neoplastic cells. (1997) U.S. Patent No. 5,688,773, issued 11-18-1997.
2. Waxman DJ, Chen L. Methods of using cytochrome P450 reductase for the enhancement of P450-based anti-cancer gene therapy. (2001) U.S. Patent No. 6,207,648, issued 3-27-2001.
3. Chiocca EA, Waxman DJ, Wei MX, Beakefield XO, Chen L. Use of viral vector encoding a cytochrome P450 gene in combination with a chemotherapeutic agent for selectively destroying neoplastic cells. (2004) European Patent No. 776,161 B1, issued 5-6-2004.

(III) JOURNAL REVIEWS

1. Yocum RR, Waxman DJ, Strominger JL. Interaction of penicillin with its receptors in bacterial membranes. (1980) Trends Biochem Sci 5, 97-101.
2. Waxman DJ, Strominger JL. Penicillin-binding proteins and the mechanism of action of β -lactam antibiotics. (1983) Ann Rev Biochem 52, 825-869.
3. Waxman DJ. Interactions of hepatic cytochromes P-450 with steroid hormones. Regioselectivity and stereospecificity of steroid metabolism and hormonal regulation of rat P-450 enzyme expression. (1988) Biochem Pharmacol 37, 71-84.

4. LeBlanc GA, Waxman DJ. Interaction of anticancer drugs with hepatic monooxygenase enzymes. (1989) Drug Metab Rev **20**, 395-439.
5. Waxman DJ. Glutathione S-transferases: role in alkylating agent resistance and possible target for modulation chemotherapy. A review. (1990) Canc Res **50**, 6449-6454.
6. Waxman DJ, Azaroff L. Phenobarbital induction of cytochrome P450 gene expression. (1992) Biochem J **281**, 577-592.
7. Waxman DJ. Regulation of liver-specific steroid metabolizing cytochromes P450: cholesterol 7 α -hydroxylase, bile acid 6 β -hydroxylase and growth hormone-responsive steroid hormone hydroxylases. (1992) Steroid Biochem Molec Biol **43**, 1055-1072.
8. Waxman DJ. Role of metabolism in the activation of dehydroepiandrosterone as a peroxisome proliferator. (1996) J Endocrinol **150**, S129-S147.
9. Waxman DJ, Chen L, Hecht JED, Jounaidi Y. Cytochrome P450-based cancer gene therapy: recent advances and future prospects. (1999) Drug Metab Rev **31**, 503-522.
10. Waxman DJ. P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR and PPAR. (1999) Arch Biochem Biophys **369**, 11-23.
11. Davey HW, Wilkins RJ, Waxman DJ. STAT5 signaling in sexually dimorphic gene expression and growth patterns. (1999) Am J Human Genetics **65**, 959-965.
12. Choi HK, Waxman DJ. Pulsatility of growth hormone signaling in liver cells: Role of the JAK/STAT5b pathway in growth hormone action. (2000) Growth Hormone & IGF Research **10 Suppl B**, S1-S8.
13. Chen L, Waxman DJ. Cytochrome P450 gene-directed enzyme prodrug therapy (GDEPT) for cancer. (2002) Current Pharmaceutical Design **8**, 1405-1416.
14. Waxman DJ, Schwartz PS. Harnessing apoptosis for improved anti-cancer gene therapy. (2003) Canc Res **63**, 8563-8572.
15. Waxman DJ, Celenza JL. Sexual dimorphism of hepatic gene expression: novel biological role of KRAB zinc finger repressors revealed. (2003) Genes & Development **17**, 2607-2613.
16. Wiwi CA, Waxman DJ. Role of hepatocyte nuclear factors in growth hormone-regulated, sexually dimorphic expression of liver cytochromes P450. (2004) Growth Factors **22**, 79-88.
17. Riddick DS, Lee C, Ramji S, Chinje EC, Cowen RL, Williams KJ, Patterson AV, Stratford IJ, Morrow CS, Townsend AJ, Jounaidi Y, Chen CS, Su T, Lu H, Schwartz PS, Waxman DJ. Cancer chemotherapy and drug metabolism. (2005) Drug Metab Dispos **33**, 1083-1096.
18. Hurst CH, Waxman DJ. Interactions of endocrine-active environmental chemicals with the nuclear receptor PXR. (2005) Toxicol & Environ Chem **87**, 299-311.
19. Schenkman JB, Waxman DJ. Editorial: David Kupfer, Ph.D. 1925-2004. (2005) J Pharm Pharmaceut Sci **8**, 601.
20. Roy P, Waxman DJ. Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer. (2006) Toxicol In Vitro **20**, 176-186.
21. Chang TKH, Waxman DJ. Synthetic drugs and natural products as modulators of constitutive androstane receptor (CAR) and pregnane X receptor (PXR). (2006) Drug Metab Rev **38**, 51-73..

22. Waxman DJ, O'Connor C. Growth hormone regulation of sex-dependent liver gene expression. (2006) Molec Endocrinol, 20, 2613-2629.
23. Jounaidi Y, Doloff JC, Waxman DJ. Conditionally replicating adenoviruses for cancer treatment. (2007) Curr Canc Drug Targets, 7, 221-237.
24. Chiocia EA, Waxman DJ. Clinical trials of suicide gene therapy. (2007) Gene Therapy, in press.
25. Bagchi G, Waxman DJ. Toxicity of ethylene glycol monomethyl ether: impact on testicular gene expression. (2008) Intl J. Andrology.
26. Huang ZZ, Aimone LD, Ator MA, Waxman DJ. Is the rat a good predictor of pharmacokinetics in humans? (2007) manuscript in preparation.

(IV) BOOK CHAPTERS

1. Strominger JL, Amanuma H, Curtis S, Kleppe G, Rasmussen J, Waxman D, Yocum RR. Drug-receptor interactions: the example of β -lactam antibiotics. (1978) Adv Pharmacol Therapeutic Vol. 10, 209-223.
2. Waxman DJ, Strominger JL. β -lactam antibiotics: biochemical modes of action. (1982) In: Morin RB, Gorman M, eds. The chemistry and biology of β -lactam antibiotics, Vol 3. New York: Academic Press, 209-285.
3. Waxman DJ. Assays for penicillin-binding proteins (PBPs). (1982) In: Morin RB, Gorman M, eds. The chemistry and biology of β -lactam antibiotics. Vol 3. New York: Academic Press, 415-417.
4. Waxman DJ. Rat hepatic cytochrome P-450: comparative studies of multiple isozymic forms. (1986) In: Ortiz de Montellano PR, ed. Cytochrome P-450: Structure, Mechanism and Biochemistry, Plenum Press, New York, 525-539.
5. Holsztynska EJ, Waxman DJ. Structural analysis of cytochromes P-450. Proposed map of functional domains. (1989) In: Schuster I, ed. Cytochrome P-450: Biochemistry and Biophysics, Taylor & Francis, 450-452.
6. Waxman DJ. Hepatic enzymes of steroid hormone metabolism. Regulation by growth hormone secretory patterns. (1989) In: Schuster I, ed. Cytochrome P-450: Biochemistry and Biophysics, Taylor & Francis, 464-471.
7. Waxman DJ. Rat hepatic P450IIA and P450IIC subfamily expression using catalytic, immunochemical, and molecular probes. (1991) Meth Enzymol 206, 249-267.
8. Koch JA, Waxman DJ. P450 phosphorylation in isolated hepatocytes and in vivo. (1991) Meth Enzymol 206, 305-315.
9. Waxman DJ. P450-catalyzed steroid hydroxylation: Assay and product identification by thin-layer chromatography. (1991) Meth Enzymol 206, 462-476.
10. Waxman DJ, Ram PA. Thyroid hormone regulation of hepatic P450 monooxygenase system. (1991) In: Progress in Thyroid Research; Gordon A, Gross J, Hennemann G, eds. Balkema Press, Rotterdam, 829-832.
11. Zimniak P, Waxman DJ. P450 metabolism of endogenous steroid hormone, bile acid and fatty acid substrates. (1993) In: Handbook of Experimental Pharmacology, Vol 105: Cytochrome P450. Schenkman JB, Greim H, eds. Springer-Verlag, Berlin-Heidelberg, 123-144.

12. Chang TKH, Chen G, Waxman DJ. Role of individual human liver P450s and other enzymes in anti-cancer drug metabolism: Drug activation and drug resistance mechanisms. (1994) In: Cytochrome P450 Biochemistry, Biophysics and Molecular Biology. M. Lechner, ed. J Libbey Eurotext, Ltd. 103-108.
13. Chen L, Waxman DJ. Metabolic activation of anticancer oxazaphosphorines by cytochrome P450: development of a model for cancer gene therapy. (1994) In: Assessment of the Use of Single Cytochrome P450 Enzymes in Drug Research. Waterman MR, Hildebrand M, eds. Springer-Verlag, 57-80.
14. Waxman DJ, Chang TKH. Hormonal regulation of liver cytochrome P450 enzymes. (1995) In: Ortiz de Montellano PR, ed. Cytochrome P450: Structure, Mechanism and Biochemistry (Second Edition), Plenum Press, New York, 391-417.
15. Waxman DJ. Steroid hormones and other physiologic regulators of liver cytochromes P450: metabolic reactions and regulatory pathways. (1996) In: Advances in Molecular and Cell Biology. Volume 14: Physiological Functions of Cytochrome P450 in Relation to Structure and Regulation. Jefcoate CR, ed. JAI Press, Greenwich CT, 337-368.
16. Chang TKH, Waxman DJ. The CYP2A subfamily. (1996) In: Cytochromes P450. Metabolic and Toxicological Aspects. Ioannides C, ed. CRC Press, Boca Raton FL, 99-134.
17. Chang TKH, Waxman DJ. Catalytic assays for human cytochrome P450. (1998) Methods Mol Biol 107, 95-102; and (2006) Methods Mol Biol 320, 73-83.
18. Chang TKH, Waxman DJ. Enzymatic Analysis of cDNA-expressed human CYP1A1, CYP1A2 and CYP1B1 with 7-ethoxyresorufin as substrate. (1998) Methods Mol Biol 107, 103-109; and (2006) Methods Mol Biol 320, 85-90.
19. Waxman DJ, Chang TKH. Spectrofluorometric analysis of CYP2A6-catalyzed coumarin 7-hydroxylation. (1998) Methods Mol Biol 107, 111-116; and (2006) Methods Mol Biol 320, 91-96.
20. Chang TKH, Crespi CL, Waxman DJ. Determination of the CYP2B6 component of 7-ethoxy-4-trifluoromethylcoumarin O-deethylation activity in human liver microsomes. (1998) Methods Mol Biol 107, 117-122; and (2006) Methods Mol Biol 320, 97-102.
21. Crespi CL, Chang TKH, Waxman DJ. High performance liquid chromatographic analysis of CYP2C8-catalyzed paclitaxel 6 α -hydroxylation. (1998) Methods Mol Biol 107, 123-127; and (2006) Methods Mol Biol 320, 103-107.
22. Crespi CL, Chang TKH, Waxman DJ. Determination of CYP2C9-catalyzed diclofenac 4'-hydroxylation by high performance liquid chromatography. (1998) Methods Mol Biol 107, 129-133; and (2006) Methods Mol Biol 320, 109-113.
23. Crespi CL, Chang TKH, Waxman DJ. CYP2C19-mediated (S)-mephenytoin 4'-hydroxylation assayed by high performance liquid chromatography with radiometric detection. (1998) Methods Mol Biol 107, 135-139; and (2006) Methods Mol Biol 320, 115-119.
24. Crespi CL, Chang TKH, Waxman DJ. CYP2D6-dependent bufuralol 1'-hydroxylation assayed by reversed-phase ion-pair high performance liquid chromatography with fluorescence detection. (1998) Methods Mol Biol 107, 141-145; and (2006) Methods Mol Biol 320, 121-125.
25. Chang TKH, Crespi CL, Waxman DJ. Spectrophotometric analysis of human CYP2E1-catalyzed *p*-nitrophenol hydroxylation. (1998) Methods Mol Biol 107, 147-152; and (2006) Methods Mol Biol 320, 127-131.
26. Waxman DJ, Chang TKH. Thin-layer chromatographic analysis of human CYP3A-catalyzed testosterone 6 β -hydroxylation. (1998) Methods Mol Biol 107, 153-161; and (2006) Methods Mol Biol 320, 133-141.

27. Crespi CL, Chang TKH, Waxman DJ. Determination of CYP4A11-catalyzed lauric acid 12-hydroxylation by high performance liquid chromatography with radiometric detection. (1998) Methods Mol Biol **107**, 163-167; and (2006) Methods Mol Biol **320**, 143-147.
28. Waxman DJ, Chang TKH. An isocratic high performance liquid chromatographic assay for CYP7A1-catalyzed cholesterol 7 α -hydroxylation. (1998) Methods Mol Biol **107**, 169-173; and (2006) Methods Mol Biol **320**, 149-152.
29. Waxman DJ, Chang TKH. Use of 7-ethoxycoumarin to monitor multiple enzymes in the human CYP1, CYP2 and CYP3 families. (1998) Methods Mol Biol **107**, 175-179; and (2006) Methods Mol Biol **320**, 153-156.
30. Waxman DJ. Sexual dimorphism of liver P450 gene expression. GH pulse-activated STAT signaling mechanisms. (1999) In: Sex-steroid interactions with growth hormone, Veldhuis JD, Giustina A, editors, Springer-Verlag, New York, 327-336.
31. Hecht JED, Waxman DJ. Selection of cytochrome P450 genes for use in prodrug activation-based cancer gene therapy. In: Gene Therapy of Cancer: Methods and Protocols. (2000) Meth Molec Med **35**, 77-83.
32. Hecht JED, Jounaidi Y, Waxman DJ. Construction of P450-expressing tumor cell lines using retroviruses. In: Gene Therapy of Cancer: Methods and Protocols. (2000) Meth Molec Med **35**, 85-94.
33. Hecht JED, Waxman DJ. In vitro methods for evaluation of P450-based anticancer gene therapy. (2000) In: Gene Therapy of Cancer: Methods and Protocols. (2000) Meth Molec Med **35**, 95-105.
34. Hecht JED, Schwartz PS, Waxman DJ. Tumor models for evaluation of P450 gene therapy in vivo. (2000) In: Gene Therapy of Cancer: Methods and Protocols. (2000) Meth Molec Med **35**, 107-118.
35. Waxman DJ. Growth hormone pulse-activated STAT5 signaling: a unique regulatory mechanism governing sexual dimorphism of liver gene expression. (2000) In: Novartis Foundation Symposium 2000; **227**, 61-81. Mechanism and biological significance of pulsatile hormone secretion.
36. Waxman DJ, Frank SJ. Growth hormone action: signaling via a JAK/STAT-coupled receptor. (2000) In: Molecular Regulation. Conn PM, Means AR, editors, Humana Press, Totawa NJ, 55-83.
37. Waxman DJ. Sex-differences in liver drug metabolism: basic biology and cellular-molecular mechanisms in rodent models. (2001) Toxicology Forum Winter 2001 Proceeding, 1-11.
38. Chioccia EA, Waxman DJ. Cytochrome P450-based gene therapies for cancer. (2003) Methods Mol Med **90**, 203-222.
39. Lobie PE, Waxman DJ. Role of STATs in the biological functions of growth hormone. (2003) In: Signal Transducers and Activators of Transcription (STATs): Activation and Biology. Sehgal PB, Levy DE, Hirano T, editors, Kluwer Academic Publishers BV, 525-544.
40. Lobie PE, Waxman DJ. Growth Hormone. (2003) In: Encyclopedia of Hormones and Regulated Cell Regulators. Henry HL, Norman AW, editors, Academic Press, New York, 208-216.
41. Waxman DJ. Nuclear receptor regulation of drug-metabolizing P450 enzymes (2004) In: Encyclopedic Reference of Molecular Pharmacology. S. Offermanns and W. Rosenthal, editors, Springer-Verlag Press, 677-682.
42. Waxman DJ, Chang TKH. Hormonal regulation of liver cytochrome P450 enzymes. (2005) In: Ortiz de Montellano PR, ed. Cytochrome P450: Structure, Mechanism and Biochemistry (Third Edition), Kluwer Academic/Plenum Publishers, NY, Chapter 9, 347-376.

43. Chang TKH, Waxman DJ. Pregnan X receptor-mediated transcription. (2005) Methods Enzymol **400**, 588-598.
44. Frank SJ, Waxman DJ. Growth hormone action: physiological and mechanistic aspects. (2006) In: Intl Rev Cytology, Jeon KW, editor, Academic Press, San Diego, in press.
45. Waxman DJ, Chang TKH. Nuclear receptor regulation of hepatic cytochrome P450 enzymes (2007) In: Encyclopedic Reference of Molecular Pharmacology, S. Offermanns and W. Rosenthal, editors, Springer-Verlag Press, in press.

(V) ABSTRACTS

1. Waxman DJ, Strominger JL. Active, water-soluble fragments of bacterial D-alanine carboxypeptidase. (1978) Fed Proc **37**, 1393.
2. Waxman DJ, Strominger JL. Structure of the COOH-terminal hydrophobic region of a penicillin-sensitive bacterial D-alanine carboxypeptidase. (1979) CSH Conf Membrane Biogenesis, 54.
3. Strominger JL, Rasmussen JR, Waxman DJ, Yocum RR. Penicillin-binding proteins as targets of the lethal action of β -lactam antibiotics. (1979) Royal Soc Conf: Penicillin 50 years after Fleming, 11.
4. Waxman DJ. Structural studies of penicillin-sensitive D-alanine carboxypeptidases and the substrate analog hypothesis. (1979) Table Ronde Roussel Uclaf: β -Lactam Antibiotics, 31-33.
5. Waxman, DJ, Strominger JL. Primary structure of the COOH-terminal hydrophobic region of two penicillin-sensitive bacterial membrane enzymes. (1980) 13th FEBS Meeting, 23.
6. Waxman DJ, Light DR, Walsh CT. Chiral sulfoxidations catalyzed by mammalian liver monooxygenases. (1981) Gord Res Conf: Drug Metabolism.
7. Waxman DJ, Ko A, Walsh C. Testosterone hydroxylations catalyzed by purified cytochrome P-450 isozymes. (1982) 4th Intl Conf Biochem Biophys Cytochrome P-450, 34.
8. Waxman DJ, Walsh C. Phenobarbital-induced rat liver cytochrome P-450: characterization of two additional isozymic forms. (1982) 4th Intl Conf Biochem Biophys Cytochrome P-450, 43.
9. Dannan GA, Waxman DJ, Guengerich FP. Sex-dependence and developmental regulation of rat liver cytochrome P-450 isoenzymes. (1984) Fed Proc, **43**, 1813.
10. Waxman DJ. Rat hepatic cytochrome P-450 isoenzyme 2c: identification as a male-specific, developmentally-induced steroid 16 α -hydroxylase. (1984) 6th Intl Symp Microsomes and Drug Oxidations. Xenobiotica **14**, Supplement 1.
11. Waxman DJ, Attisano C, Holsztyńska EJ, Krishnan M. Metabolism of endogenous steroids catalyzed by rat hepatic cytochrome P-450. (1985) 4th Intl Symp Comparative Biochemistry: Cytochrome P-450, Janssen Research Foundation, 78-79.
12. Waxman DJ, Holsztyńska EJ, Krishnan M, Attisano C. Biochemistry and regulation of rat hepatic P-450 cholesterol 7 α -hydroxylase (P-450 Ch7 α). (1985) Pharmacologist **27**, 115.
13. Clarke L, Waxman DJ. Biochemical characterization of human liver folylpolyglutamate synthetase (FPGS). (1985) Pharmacologist **27**, 151.
14. Holsztyńska EJ, Waxman DJ. Are Ca⁺²-Calmodulin-dependent phosphatase(s) involved in P-450 regulation? (1985) Gord Res Conf: Drug Metabolism.

15. Yeowell HN, Waxman DJ, Linko P, Goldstein JA. Repression of cytochrome P-450 2c and its mRNA by 3,4,5,3',4',5'-hexachlorobiphenyl (HCB), 3-methylcholanthrene (3-MC) and phenobarbital (PB) in livers from male rats. (1986) Fed Proc **45**, 319 and (1987) Environ Health Perspect **75**, 124.
16. Waxman DJ, Clarke L. Human liver folylpolyglutamate synthetase (FPGS): biochemical characterization and interactions with folates and antifolates. (1986) Proc Am Assoc Cancer Res **27**, 255 and (1986) Methotrexate Update **Dec**, 6.
17. Waxman DJ, Frey AB, Wadhwa A, Clarke L, Kreibich G. 3-(Trifluoromethyl)-3-(m-[¹²⁵I]iodophenyl)diazirine ([¹²⁵I]TID) labels a substrate-binding site of rat hepatic cytochrome P-450 (P-450) form PB-4. (1986) Fed Proc **45**, 1506 and (1986) Cord Res Conf: Chemistry and Biology of Pyrroles.
18. Dannan GA, Guengerich FP, Waxman DJ. Age-dependent expression and role of gonadal steroids in regulation of rat hepatic cytochrome P-450 and other enzymes. (1986) Fed Proc **45**, 1662.
19. Holsztyńska EJ, Waxman DJ. Regulation of rat hepatic cytochrome P-450 cholesterol 7 α -hydroxylase (P-450Ch7 α) inactivation by a microsomal system sensitive to sodium fluoride and Calmodulin antagonists. (1986) Fed Proc **45**, 1662.
20. LeBlanc GA, Waxman DJ. Effects of cisplatin and cyclophosphamide on rat hepatic cytochrome P-450 isozymes. (1986) 4th New Engl Membr Enzyme Conf, 13.
21. Holsztyńska EJ, Waxman DJ. A novel microsomal process that inactivates cytochrome P-450 Ch7 α . (1986) 4th New Engl Membr Enzyme Conf, 14.
22. Wright JE, Cucchi CA, Rosowsky A, Cualing H, Bernal SD, Koch JA, Waxman DJ, Frei E III. Dihydrofolate reductase (DHFR) from methotrexate (MTX) resistant human squamous cell carcinoma for monoclonal antibody generation. (1987) Proc Am Assoc Cancer Res **28**, 297.
23. LeBlanc GA, Waxman DJ. Differential modulation of rat hepatic cytochrome P-450 enzymes upon exposure to cisplatin and cyclophosphamide. (1987) Proc Am Assoc Cancer Res **28**, 315.
24. Waxman DJ, Morville A, Adesnik M. Developmental and hormonal regulation of rat hepatic P-450 form 2c: studies using a cloned cDNA probe. (1987) 2nd Airlie House Conf: P-450 Gene Regulation and (1987) 5th New Engl Membr Enzyme Conf.
25. Yeowell HN, Waxman DJ, Linko P, Goldstein JA. Induction of rat cytochrome P-450 3 and its mRNA by 3,4,5,3',4',5'-hexachlorobiphenyl (HCB): comparison to the induction of P-450c in liver and extrahepatic tissues. (1987) Fed Proc **46**, 2141.
26. Park SS, Waxman DJ, Sundaresan GM, Miller H, Schenkman JB, Gelboin HV. Monoclonal antibodies to rat liver cytochrome P-450 2c/RLM5: characterization and regiospecific inhibition of steroid hormone metabolism. (1987) Fed Proc **46**, 2142.
27. Waxman DJ, Lapenson DP, Park SS, Attisano C, Gelboin HV. Monoclonal antibodies (MAbs) inhibitory to rat hepatic cytochromes P-450: use as probes for P-450-dependent steroid hydroxylations. (1987) Fed Proc **46**, 2142.
28. Waxman DJ. Hepatic cytochromes P-450: regulation of endogenous steroid metabolism. (1987) Cord Res Conf: Hormonal Carcinogenesis.
29. Clarke L, Waxman DJ. Cytochrome P-450 mediated metabolism of cyclophosphamide and ifosfamide. (1987) 5th New Engl Membr Enzyme Conf.

30. LeBlanc GA, Morrissey JJ, Waxman DJ. Feminization of adult male rat hepatic enzyme expression by the anticancer drug cisplatin. (1987) 5th New Eng Membr Enzyme Conf.
31. Holsztyńska EJ, Waxman DJ. Computer-aided structural analysis of rat liver P-450 cytochromes. (1987) 5th New Engl Membr Enzyme Conf and (1988) 6th Intl Conf Biochem Biophys Cytochrome P-450, 30.
32. Waxman DJ, LeBlanc GA, Morrissey JJ, Staunton J. Androgenic programming and pituitary control of adult male-specific rat liver P-450 forms RLM2 and 2a. (1988) FASEB J 2, A1012 and (1988) 14th Intl Cong Biochem, Th: 136, 97.
33. LeBlanc GA, Morrissey JJ, Waxman DJ. Femization of the profile of hepatic steroid metabolizing enzymes by cisplatin. (1988) FASEB J 2, A1012.
34. Yeowell HN, Waxman DJ, LeBlanc GA, Linko P, Goldstein JA. Repression of the male-specific hepatic cytochrome P-450 form 2c and its mRNA by 3,4,5,3',4',5'-hexachlorobiphenyl (HCB) is not mediated by effects on serum testosterone levels. (1988) FASEB J 2, A1341.
35. Friedberg T, Kissel W, Honscha W, Waxman D, Oesch F. Antibodies targeted against constant and hypervariable regions of P-450 IIB1 and P-450 IIB2. (1988) 6th Intl Conf Biochem Biophys Cytochrome P-450, 19.
36. Waxman DJ. Cytochrome P-450 enzymes in rat hepatic tissue. Interactions with steroid hormones and anti-cancer drugs. (1988) 6th Intl Conf Biochem Biophys Cytochrome P-450, 91.
37. Holsztyńska E, Waxman D, Zimniak P, Radomska A, Lester R. Cytochromes P-450 involved in the hydroxylation of lithocholic acid. (1988) Hepatology 8, 1259.
38. Radomska A, Zimniak P, Lester R, Holsztyńska E, Waxman D. The hydroxylation of bile acids by human liver microsomes. (1988) Hepatology 8, 1362.
39. Zimniak P, Radomska A, Lester R, Holsztyńska E, Waxman D. The detoxification of lithocholic acid. (1988) Hepatology 8, 1362.
40. Holsztyńska E, Waxman DJ, Jurka J. Studies on rat liver cytochromes P-450 using comparative sequence analysis. (1988) 2nd Ann Symp Protein Soc, 91.
41. Ng S, Waxman DJ. Steroid metabolism in the isolated perfused rat liver. (1988) 6th New Engl Membr Enzyme Conf.
42. Waxman DJ, Morrissey JJ, LeBlanc GA. Regulation of female-predominant rat hepatic P-450 enzymes by gonadal and pituitary hormones. (1988) J Cell Biol 107, 198a.
43. Morrissey JJ, Lapenson DP, LeBlanc GA, Waxman DJ. Pituitary control of hepatic NADPH cytochrome P-450 reductase. (1988) J Cell Biol 107, 408a.
44. Shapiro BH, MacLeod JN, Pampori NA, Morrissey JJ, Lapenson DP, Waxman DJ. Plasma growth hormone patterns and hepatic P-450 expression in adult male rats treated neonatally with monosodium glutamate (MSG). (1989) FASEB J 3, A1023.
45. Waxman DJ. The role of cytochrome P-450 in metabolism of chemotherapeutic drugs. (1989) US-Ipn Cancer Coop Mtg: Cytochrome P-450 and Carcinogenesis.
46. Waxman DJ, Clarke L, Ng S. Oxidative metabolism of thio-TEPA. Role of hepatic cytochrome P-450. (1989) Proc Am Assoc Cancer Res 30, 463 and (1989) 7th New Engl Membr Enzyme Conf.

47. Ram PA, Waxman DJ. Regulation of cytochrome P-450 levels in the thyroxine-depleted methimazole-treated rat. (1989) 7th New Engl Membr Enzyme Conf.
48. Radomska A, Zimniak P, Lapenson DP, Falany J, Iscan M, Lester R, Waxman DJ. Bile acid hydroxylation by human liver microsomes and vaccinia virus-expressed cytochrome P-450 hPCN1 and hPCN3. (1989) 7th New Engl Membr Enzyme Conf.
49. Sundseth SS, Waxman DJ. Regulation of P-450 cholesterol 7 α -hydroxylase protein. (1990) FASEB J 4, A534 and (1990) 1st Mass Conf Cholesterol.
50. Stegeman JJ, Woodin BR, Waxman DJ. Structural relatedness of mammalian cytochromes P-450 IIB and cytochrome P-450B from the marine fish scup (*Stenotomus chrysops*). (1990) FASEB J 4, A739.
51. Waxman DJ, Morrissey JJ, Naik S, Jauregui H. High level, long-term responsiveness of primary rat hepatocyte P-450s to phenobarbital. (1990) FASEB J 4, A887.
52. Waxman DJ, LeBlanc GA. Mechanisms of cyclophosphamide (CP) action on hepatic P-450 expression. (1990) Proc Am Assoc Cancer Res 31, 397.
53. Radomska A, Zimniak P, Falany J, Iscan M, Lester R, Waxman DJ. Bile acid hydroxylation by human liver microsomes and vaccinia virus-expressed cytochrome P-450 hPCN1 and hPCN3. (1990) FASEB J 4, A1972.
54. Waxman DJ, Sundseth SS. Hepatic P450 cholesterol 7 α -hydroxylase. In vivo regulation at the protein and mRNA level in response to mevalonate, diurnal rhythm and bile acid feedback. (1990) 8th Intl Symp Microsomes and Drug Oxidations, 97.
55. Iscan M, Radomska A, Zimniak P, Waxman DJ. Inhibition studies of rat liver lithocholic acid 6 β -hydroxylase. (1990) 8th Intl Symp Microsomes and Drug Oxidations, 110.
56. Waxman DJ, Ram PA. Thyroid hormone regulation of hepatic P-450 monooxygenase system. (1990) 10th Intl Thyroid Congress, 39.
57. Zimniak P, Holsztyńska EJ, Radomska A, Iscan M, Lester R, Waxman DJ. Cytochromes P450 involved in bile acid hydroxylation and detoxification. (1990) Falk Symposium 57: Hepatic metabolism and disposition of endo- and xenobiotics.
58. Waxman DJ. Hormonal control of drug metabolism. (1990) 12th Europ Workshop Drug Metab, 6.
59. Weber G, Waxman DJ. Bioactivation of cyclophosphamide and ifosfamide by hepatic P450s. (1990) 8th New Engl Membr Enzyme Conf.
60. Srivastava P, Waxman DJ. High resolution IEF/Western blot analysis of human GSTs. (1990) 8th New Engl Membr Enzyme Conf.
61. Ng S, Waxman DJ. Biotransformation of thio-TEPA to TEPA: Role of constitutive P450s and modulation in vivo. (1990) 8th New Engl Membr Enzyme Conf.
62. Park SS, Walker W, Aoyama T, Lapenson D, Waxman DJ, Gonzalez FJ, Gelboin HV. Monoclonal antibodies that detect cytochrome b₅ of rat and rabbit and expressed from human cDNA. (1991) FASEB J 5, A1164.
63. Ram PA, Waxman DJ. Thyroid hormone dependence of NADPH P450 reductase expression. (1991) FASEB J 5, A1165.

64. Zimniak P, Radomska A, Lester R, Waxman DJ. Cytochromes P450 involved in the 6-hydroxylation of bile acids in rats and humans. (1991) 15th Intl Cong Biochem.
65. Waxman DJ, LeBlanc GA, Sundseth SS, Weber GF. Platinum anti-cancer drugs modulate P450 mRNA levels and differentially alter hepatic drug and steroid hormone metabolism in male and female rats. (1991) Gord Res Conf: Chemotherapy of Experimental and Clinical Cancer.
66. Waxman DJ, Pampori NA, Ram PA, Agrawal AK, Shapiro BH. Signalling elements in circulating growth hormone patterns that regulate sexually dimorphic expression of hepatic P450. (1991) Gord Res Conf: Hormone Action.
67. Waxman DJ. Liver P450-catalyzed steroid biotransformation: Metabolic pathways and endocrine regulation. (1991) Intl Ares-Serono Symp Molec View Steroid Biosynth Metab. 37.
68. Sundseth SS, Waxman DJ. Sex-dependent expression and clofibrate inducibility of cytochrome P450 4A fatty acid omega hydroxylases. Male specificity of liver and kidney CYP4A2 mRNA and tissue-specific regulation by growth hormone and testosterone. (1992) J Cell Biochem 16C, 47.
69. Nanji AA, Zhao S, Sadrzadeh SHH, Dannenberg A, Waxman DJ. Microsomal fatty acid changes in experimental alcoholic liver injury: relationship to levels of cytochrome P450 2E1 (CYP 2E1) and microsomal conjugated dienes. (1992) Gastroenterology 102, A859.
70. Waxman DJ, Ram PA, Zhao S, Sundseth SS, Alberta JA. Regulation of P450-dependent hepatic steroid hydroxylation by growth hormone and thyroxine. (1992) 9th Intl Symp Microsomes and Drug Oxidations
71. Nanji AA, Lamb RC, Sadrzadeh SMH, Zhao S, Dannenberg AJ, Waxman DJ. Liver microsomal phospholipases A and C in experimental alcoholic liver injury: relationship to arachidonic acid and cytochrome P450 2E1. (1992) Hepatology, 16, 111A.
72. Nanji AA, Zhao S, Sadrzadeh SMH, Waxman DJ. Serial changes in cytochromes P450 2E1, 4A, and 2B1 in experimental alcoholic liver injury. (1992) Hepatology 16, 112A.
73. Chang TKH, Weber G, Crespi C, Waxman DJ. Differential activation of cyclophosphamide and ifosfamide by cytochromes P450 2B and 3A in human liver microsomes. (1993) Gord Res Conf: Drug Metabolism.
74. Ram PA, Waxman DJ. Induction of cytochrome P450 4A (CYP) and acyl Coa oxidase mRNAs by dehydroepiandrosterone sulfate (DHEA-S) in primary rat hepatocyte culture. (1993) Endocrine Soc 75th Annu Mtg, 202 and (1993) 8th Intl Conf Cytochrome P450: Biochemistry Biophysics and Molecular Biology.
75. Waxman DJ, Chang TKH, Chen G. Interactions of anti-cancer drugs with cytochromes P450 and glutathione S-transferases: drug activation and drug resistance mechanisms. (1993) 5th North Am ISSX Conf.
76. Nanji AA, Zhao S, Sadrzadeh SMH, Waxman DJ. Evaluation of in vivo cytokine gene expression in chronic ethanol-fed rats. (1993) AASLD meeting.
77. Dannenberg AJ, Yang EK, Waxman DJ. Dietary lipids coordinately regulate the expression of genes coding for xenobiotic metabolizing enzymes. (1993) AASLD Meeting.
78. Waxman DJ, Chang TKH, Chen G. Role of individual human liver P450s and other enzymes in anti-cancer drug metabolism: drug activation and drug resistance mechanisms. (1993) 8th Intl Conf Cytochrome P450: Biochemistry, Biophysics and Molecular Biology.

79. Waxman DJ. Cytochrome P450 -- A metabolic and regulatory interface between hormones and xenobiotics. (1993) Burroughs-Wellcome Sympos: Endocrine Toxicant Interactions.
80. Chen G, Waxman DJ. Complete reversal by thaliblastine (TBL) of 490-fold Adriamycin (AdR) resistance in multidrug resistant (MDR) human breast cancer cells: evidence that multiple biochemical changes in MDR cells do not necessarily indicate multiple determinants for drug resistance. (1994) Proc Am Assoc Cancer Res 35, 347.
81. Nanji AA, Zhao S, Sadrzadeh SMH, Khetry U, Tahan S, Waxman DJ. Markedly enhanced cytochrome P450 2E1 induction and lipid peroxidation is associated with severe liver injury in fish oil-ethanol fed rats. (1994) FASEB J 8.
82. Zhao S, Waxman DJ. Interaction of sex- and growth hormone (GH)-dependent liver nuclear factors with CYP2C12 promoter. (1994) FASEB J 8, A1250.
83. Lee YH, Alberta JA, Gonzalez FJ, Waxman DJ. Multiple, functional DBP sites on the promoter of the cholesterol 7 α -hydroxylase P450 gene promoter. (1994) FASEB J 8, A1252.
84. Chang TKH, Chen G, Waxman DJ. Impact of liver cytochrome P450 modulators on thio-TEPA anti-tumor activity and host toxicity in a rodent tumor model. (1994) Can J Physiol Pharmacol 72 (Suppl 1), 196.
85. Waxman DJ. Regulation of liver P450 expression by steroids, foreign chemicals and liver transcription factors. (1994) 10th Intl Symp Microsomes and Drug Oxidations, 68-70.
86. Chang TKH, Gonzalez FJ, Waxman DJ. Evaluation of triacetyldandomycin, α -naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. (1994) 10th Intl Symp Microsomes and Drug Oxidations, 481.
87. Rifkind AB, Lee C, Chang TKH, Waxman DJ. P450 dependent arachidonic acid metabolism by vaccinia virus expressed human P450 isoforms and by human liver microsomes. (1994) 10th Intl Symp Microsomes and Drug Oxidations, 522.
88. Wei MX, Tamiya T, Chase M, Waxman DJ, Boviatsis EJ, Kowall NW, Hochberg FH, Breakefield XO, Chiocca EA. Therapy of meningeal neoplasia in mice with cyclophosphamide-activating cytochrome P450 2B1 gene. (1994) CSH Conf Gene Therapy and (1994) Growth Control in CNS Tumors Conf.
89. Chiocca EA, Wei MX, Tamiya T, Waxman DJ, Breakefield XO. Brain tumor gene therapy in mice with a novel "suicide" gene: the cyclophosphamide-activating CYP2B1 gene. (1994) Congr Neurological Surgeons.
90. Waxman DJ. Regulation of liver P450 gene expression by endogenous hormones and liver transcription factors. (1994) 6th North Am ISSX Conf, 16.
91. Wei MX, Chase M, Ono Y, Li FQ, Waxman DJ, Hochberg FH, Breakefield XO, Chiocca EA. A novel drug-sensitivity gene, cytochrome-P450-2B1, activates cyclophosphamide. (1995) J Cell Biochem S21A, 428.
92. Chang TKH, Maurel P, Waxman DJ. Enhanced activation of cyclophosphamide and ifosfamide in primary cultures of human hepatocytes treated with inducers of CYP2B, CYP2C and CYP3A. (1995) 7th Intl Cong Toxicol, 35-P-37.
93. Code EL, Crespi CL, Penman BW, Gonzalez FJ, Chang TKH, Waxman DJ. Immunochemical and enzymatic characterization of human hepatic levels of CYP2B6. (1995) 4th Intl ISSX Mtg 8, 100 and (1995) 13th New Engl Membr Enzyme Conf.

94. Code EL, Melvin WT, Penman BW, Waxman DJ, Crespi CL. Characterization of a monoclonal antibody selectively inhibitory to human CYP2A6. (1995) 4th Intl ISSX Mtg. 8, 101.
95. Chang TKH, Goldstein JA, Waxman DJ. Cyclophosphamide 4-hydroxylation and ifosfamide 4-hydroxylation catalyzed by recombinant human CYP2C8, CYP2C19 and allelic variants of CYP2C9 and CYP2C18 expressed in yeast. (1995) 4th Intl ISSX Mtg. 8, 361.
96. Crespi CL, Code EL, Penman BW, Waxman DJ. An activity-based method for integrating metabolism data from cDNA-expressed cytochrome P450 enzymes to the balance of enzymes in human liver microsomes. (1995) Gord Res Conf: Drug Metabolism; (1995) 4th Intl ISSX Mtg. 8, 420; and (1995) Zurich P450 Meeting.
97. Waxman DJ. Metabolism of DHEA and related steroids: interaction with liver cytochromes P450 (CYPs). (1995) Intl Symp DHEA Transformation, 29.
98. Yu L, Drewes P, Gustafsson K, Waxman DJ. Activation and deactivation of oxazaphosphorine antitumor drugs catalyzed by distinct subsets of cytochrome P450s. (1995) 13th New Engl Membr Enzyme Conf.
99. Choi HK, Zhao S, Waxman DJ. Binding of a female-specific, continuous growth hormone-activated nuclear factor to the CYP 2C12 promoter. (1995) 13th New Engl Membr Enzyme Conf.
100. Park SH, Ram P, Choi HK, Waxman DJ. GH activation of Stat proteins: proposed role in liver P450 gene regulation. (1995) 13th New Engl Membr Enzyme Conf.
101. Yu L, Gustafsson K, Drewes P, Waxman DJ. Modulation of P450 metabolism of oxazaphosphorines: activation and deactivation/neurotoxication are catalyzed by distinct subsets of liver P450s. (1996) Proc Am Assoc Canc Res 37, 378.
102. Yi W, Kim SO, Jiang J, Park SH, Kraft AS, Waxman DJ, Frank SJ. Growth hormone receptor cytoplasmic domain differentially promotes Stat 3 and Stat 5b tyrosine phosphorylation by the Jak2 kinase. (1996) 10th Intl Congr Endocrinol, 55 and (1996) J Invest Med 44, A260.
103. Gebert CA, Park SH, Waxman DJ. Regulation of liver Stat 5 activation in hepatocyte culture by the temporal pattern of growth hormone (GH) stimulation. (1996) FASEB J 10, A996.
104. O'Leary KA, Li HC, Ram PA, McQuiddy P, Waxman DJ, Kasper CB. Identification of a thyroid responsive element in the NADPH cytochrome P450 oxidoreductase promoter. (1996) FASEB J 10, A1499.
105. Waxman DJ, Gebert CA, Park SH, Ram PA, Choi HK. Growth hormone regulation of liver steroid hydroxylase CYPs: proposed role of Stat proteins in male-specific liver gene expression. (1996) 11th Intl Symp Microsomes Drug Oxidations, 32.
106. Zhou YC, Peters JM, Ram PA, Lee SST, Gonzalez FJ, Waxman DJ. Peroxisome proliferator-activated receptor α (PPAR α) mediates gene induction by dehydroepiandrosterone 3 β -sulfate (DHEA-S). (1996) 11th Intl Symp Microsomes Drug Oxidations, 209.
107. Ram PA, Waxman DJ. Interaction of growth hormone-activated STATs with nuclear JAK2 tyrosine kinase and SH2-containing phosphotyrosine phosphatase. (1996) Gord Res Conf: Peptide Growth Factors and (1997) 15th New Engl Membr Enzyme Conf.
108. Li HC, Waxman DJ. Mechanism of thyroid hormone induction of NADPH-cytochrome P450 reductase. (1996) 14th New Engl Membr Enzyme Conf.
109. Hecht JED, Waxman DJ. Role of prostaglandin H synthetase in the activation of cyclophosphamide. (1996) 14th New Engl Membr Enzyme Conf.

110. Jounaidi Y, Waxman DJ. Evaluation of human CYPs as candidate genes for cancer gene therapy strategies. (1996) 14th New Engl Membr Enzyme Conf.
111. Zhou YC, Waxman DJ. Activation of PPAR by chlorinated hydrocarbons and endogenous steroids. (1997) Superfund Basic Res Program Conf.
112. Waxman DJ, Udy GB, Towers RP, Snell RG, Wilkins RJ, Park SH, Davey HW. Loss of sexually dimorphic responses to growth hormone pulses in STAT5b gene disrupted mice. (1997) 79th Endocrine Society Meeting, 72.
113. Ram PA, Waxman DJ. Interaction of growth hormone-activated STATs with nuclear JAK2 tyrosine kinase and SH2-containing phosphotyrosine phosphatase SHP-1. (1997) 79th Endocrine Society Meeting, 342.
114. Roy P, Yu L, Waxman DJ. Metabolism of oxazaphosphorine anti-cancer drugs by human P450 enzymes. (1997) Cord Res Conf: Drug Metabolism.
115. Davey HW, Towers RP, Wilkins RJ, Park SH, Ram PA, Waxman DJ, Udy GB. Loss of sexually dimorphic growth and liver gene expression in STAT5B-deficient mice. (1997) Queenstown Molecular Biology Meeting.
116. Waxman DJ, Park SH, Ram PA, Udy GB, Towers RP, Snell RG, Wilkins, RJ, Davey HW. JAK kinase, STAT transcription factors, and growth hormone (GH) regulation of sex-dependent liver P450 gene expression. (1997) FASEB J 11, A779.
117. Raychowdhury M, Jounaidi Y, Hecht J, Waxman DJ. Cytochrome P450-based cancer gene therapy strategies. (1997) Berlin Symposium: Microsomes, Drug Oxidations, and Clinical Pharmacology Symposium.
118. Zhou YC, Waxman DJ. Cross-talk between PPAR and JAK-STAT signaling pathways regulating liver P450 expression. (1997) 15th New Engl Membr Enzyme Conf.
119. Wang Y, Waxman DJ. Phenobarbital induction of P450s in the stable rat liver cell line CWSV-1. (1997) 15th New Engl Membr Enzyme Conf.
120. Waxman DJ. Regulation of sex-dependent liver cytochromes P450 via STAT protein-dependent growth hormone signal transduction pathways. (1997) Society of Toxicology Canada, Signal Transduction Symposium.
121. Gebert CA, Waxman DJ. Termination of growth hormone pulse-induced STAT5b signaling. (1998) 80th Endocrine Society Meeting, 85.
122. Waxman DJ, Gebert CA. Down-regulation of liver JAK2-STAT5b signaling by female pattern of continuous plasma growth hormone. Proposed role of phosphotyrosine phosphatases. (1998) 80th Endocrine Society Meeting, 144.
123. Zhou YC, Waxman DJ. JAK/STAT interaction with PPAR α . (1998) 80th Endocrine Society Meeting, 144.
124. Waxman DJ, Gebert CA, Park SH, Ram PA. Role of the STAT signal transduction pathway in growth hormone-regulated P450 gene control. (1998) 12th Intl Symp Microsomes and Drug Oxidations, PL1-2.
125. Zhou YC, Waxman DJ. Cross-talk between JAK-STAT and PPAR signaling pathways. Growth hormone (GH) inhibition of PPAR α activity mediated by STAT5b. (1998) 12th Intl Symp Microsomes and Drug Oxidations, 123.

126. Hecht JED, Waxman DJ. Role of prostaglandin H synthase (PGHS) in cooxidation leading to activation of the anticancer drug cyclophosphamide (CPA). (1998) 12th Intl Symp Microsomes and Drug Oxidations, 213.
127. Jounaidi Y, Hecht JED, Waxman DJ. Use of human cytochrome P450 genes for cancer gene therapy. (1998) 12th Intl Symp Microsomes and Drug Oxidations, 214.
128. Chen L, Waxman DJ. Cytochrome P450 and gene therapy for cancer. (1998) 12th Intl Symp Microsomes and Drug Oxidations, S12-1.
129. Huang Z, Waxman DJ. Interaction of cyclophosphamide with other drugs and P450 inhibitors. (1998) Gord Res Conf: Drug Metabolism.
130. Roy P, Yu LJ, Crespi CL, Waxman DJ. Cyclophosphamide and ifosfamide activation by human cytochromes P450. (1998) Am Assoc Pharmaceut Sci. Annual meeting.
131. Waxman DJ, Park SH, Gebert CA. Sexual dimorphism of liver P450 gene expression: growth hormone pulse-activated STAT signaling mechanisms. (1998) Serono Symposium: Sex-steroid Interactions with Growth Hormone, 34.
132. Zhou Y, Waxman DJ. Inhibitory cross-talk between JAK2/STAT5b and PPAR α . (1999) 81st Endocrine Society Meeting, 108.
133. Delesque-Touchard N, Waxman DJ. Synergistic action of growth hormone-regulated liver nuclear factors HNF3 and HNF6 on CYP2C12 promoter. (1999) 81st Endocrine Society Meeting, 157.
134. Ram PA, Waxman DJ. Role of SOCS/CIS proteins in inhibition of growth hormone (GH) activation of STAT5b. (1999) 81st Endocrine Society Meeting, 386.
135. Waxman DJ, Jounaidi Y, Hecht JED, Schwartz PS, Huang Z. P450-based cancer gene therapy: recent advances. (1999) 11th Intl Conf Cytochrome P450, 46.
136. Davey HW, Park SH, Grattan D, McLachlan MJ, Waxman DJ. STAT5b-deficient mice are growth hormone (GH) pulse-resistant: role of STAT5b in sex-specific liver P450 expression. (1999) 11th Intl Conf Cytochrome P450, 102.
137. Schwartz PS, Waxman DJ. Cyclophosphamide induces apoptosis in a P450-based gene therapy system. (1999) Gordon Res Conf: Cell Death.
138. Belcourt MF, Waxman DJ, Goss K, King I, Bermudes D, Lin S. Activation of cyclophosphamide by tumor-targeting Salmonella typhimurium. (1999) Molec Targets and Cancer Therapeutics, AACR Conf (Clin Canc Res), 94.
139. Jounaidi Y, Waxman DJ. P450-enhanced cytotoxicity of the bioreductive drug tirapazamine: combination with cyclophosphamide for P450/P450-reductase-based cancer gene therapy. (1999) Molec Targets and Cancer Therapeutics, AACR Conf (Clin Canc Res), 117.
140. Huang Z, Roy P, Waxman DJ. Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. (1999) 9th North Am ISSX Conf 15, 118.
141. Bains SK, Ram PA, Waxman DJ. Growth hormone receptor mediates nuclear translocation of STAT5b and its deactivation. (1999) 17th New Engl Membr Enzyme Conf.
142. Waxman DJ, Choi HK, Park SH, Delesque-Touchard N, Bains SK, Ram PA. Pulsatility of growth hormone signaling mediated by STAT5b. (2000) 82nd Endocrine Society Meeting, 16.

143. Ram PA, Waxman DJ. Role of CIS in desensitization of STAT5b signaling by continuous GH. (2000) 82nd Endocrine Society Meeting, 147.
144. Bains SK, Ram PA, Waxman DJ. Growth hormone receptor (GHR)-mediated nuclear translocation of STAT5b. (2000) 82nd Endocrine Society Meeting, 147.
145. Tannenbaum C, Choi HK, Gurd W, Waxman DJ. Temporal relationship between spontaneous GH secretory profiles and hepatic STAT5 activity in male and female rats. (2000) 82nd Endocrine Society Meeting, 158.
146. Choi HK, Waxman DJ. Role of GH pulses in activation of JAK/STAT5 signal transduction pathway and male-specific liver P450 gene expression. (2000) FASEB J 14, A1432.
147. Schwartz PS, Waxman DJ. Cyclophosphamide induces caspase 9-dependent apoptosis in P450 gene-based anticancer therapy. (2000) FASEB J 14, A1515.
148. Waxman DJ, Delesque-Touchard N, Zhou YC, Park SH, Choi HK, Ram PA. Regulation of liver CYPs by growth hormone-stimulated STAT5 signaling. (2000) 13th Intl Symp Microsomes and Drug Oxidations.
149. Hurst C, Choi HK, Waxman DJ. Inhibitory crosstalk between growth hormone-activated STAT5b and PPAR α in a rat liver model. (2000) Gordon Res Conf: Mechanisms of Toxicity, and (2001) Soc of Toxicology.
150. Waxman DJ, Jounaidi Y, Schwartz PS, Huang Z. P450-based cancer gene therapy: recent advances. (2000) AACR Special Meeting: New Targets for Cancer Intervention.
151. Waxman DJ. Receptor-mediated signaling events in cytochrome P450 gene regulation. (2000) Early Toxicity Screening in Drug Discovery Conf.
152. Jounaidi Y, Waxman DJ. Anti-angiogenic scheduling of cyclophosphamide improves the efficacy of P450/P450 reductase-based cancer gene therapy. (2000) Intl Conf of Gene Therapy of Cancer, San Diego, California.
153. Park SH, Yamashita H, Rui H, Waxman DJ. Growth hormone-induced serine phosphorylation of STAT5A and STAT5B: impact on STAT5 transcriptional activity. (2001) 83rd Endocrine Society Meeting, Denver, Colorado, 176.
154. Park SH, Waxman DJ. Interaction of STAT5b with liver nuclear factors HNF3 β and HNF1 α . Impact on the regulation of growth hormone pulse-dependent liver cytochrome P450 gene expression. (2001) 83rd Endocrine Society Meeting, Denver, Colorado, 176 and (2002) Keystone Symposium, JAKs and STATs: activation and biological impact.
155. Park SH, Waxman DJ. Nucleocytoplasmic shuttling of growth hormone (GH)-activated STAT5B. (2001) 83rd Endocrine Society Meeting, Denver, Colorado, 341.
156. Shipley JM, Zhao Y, Waxman DJ. PPAR inhibition of STAT5-regulated gene transcription. (2001) 83rd Endocrine Society Meeting, Denver, Colorado, 341.
157. Davey HW, Xie T, McLachlan MJ, Wilkins RJ, Waxman DJ, Grattan DR. STAT5b is required for growth hormone-induced liver *Igf-I* gene expression. (2001) 83rd Endocrine Society Meeting, Denver, Colorado, 344.
158. Hecht JED, Waxman DJ. Improving P450/prodrug activation-based anticancer gene therapy. (2001) New England Drug Metabolism Discussion Group: First Summer Symposium, p.24.

159. Jounaidi Y, Schwartz PS, Hecht J, Chen CS, Waxman DJ. P450-based cancer gene therapy: recent advances in the laboratory and the clinic. (2001) 12th Intl Conf Cytochrome P450, La Grande Motte, France and (2001) 10th Intl Conf Gene Therapy of Cancer, San Diego, California.
160. Hurst CH, Waxman DJ. Environmental xenobiotics (monoester phthalates) activate PPAR α and PPAR γ -mediated transcription. (2001) Superfund Basic Research Program Meeting: Assessing risks of hormonally active agents, Gainesville, FL.
161. Ahluwalia A, Waxman DJ. Use of oligonucleotide microarrays for expression profiling of CYP genes in rat liver. (2001) 19th New Engl Membr Enzyme Conf.
162. Chen C, Waxman DJ. HPLC-fluorescent method for determination of chloroacetaldehyde and 4-hydroxycyclophosphamide, metabolites of the prodrug cyclophosphamide. (2001) 19th New Engl Membr Enzyme Conf.
163. Goss K, Waxman DJ. Improving cytochrome P450 based gene therapy of cancer. The search for a better enzyme catalyst by DNA shuffling mutagenesis. (2001) 19th New Engl Membr Enzyme Conf.
164. Liu D, Waxman DJ. Post-transcriptional regulation of hepatic NADPH-P450 reductase by thyroid hormone: independent effect on poly (A) tail length and mRNA stability. (2001) 19th New Engl Membr Enzyme Conf.
165. Wiwi C, Waxman DJ. Role of liver-enriched transcription factors in GH regulation of sexually dimorphic cytochrome P450 expression. (2001) 19th New Engl Membr Enzyme Conf.
166. Wiwi C, Waxman DJ. Sex-dependent expression of rat hepatic nuclear factors. (2001) 19th New Engl Membr Enzyme Conf.
167. Hurst CH, Waxman DJ. Trans-activation of PPAR α and PPAR γ by phthalate monoesters. (2002) 19th New Engl Member Enzyme Conf and (2002) Society of Toxicology Abstract.
168. Waxman DJ, Park SH, Ahluwalia A, Wiwi CA. Sex-dependent regulation of cytochrome P450 and other liver-expressed genes by growth hormone-stimulated STAT5b signaling. (2002) 84th Endocrine Society Meeting, San Francisco, CA, 43.
169. Wiwi C, Waxman DJ. Role of liver-enriched transcription factors in GH regulation of sexually dimorphic cytochrome P450 (CYP) expression. (2002) 84th Endocrine Society Meeting, San Francisco, CA, 556.
170. Ahluwalia A, Waxman DJ. Sexual dimorphism of rat liver gene expression: regulatory role of growth hormone revealed by DNA microarray analysis. (2002) 84th Endocrine Society Meeting, San Francisco, CA, 558 and (2002) Boston University-Humboldt University Bioinformatics Workshop.
171. Ahluwalia A, Waxman DJ. Global gene expression profiling in rat liver using oligonucleotide microarrays: evaluation of the regulatory role of hormones and xenobiotics. (2002) New England Drug Metabolism Discussion Group Summer Symposium, Worcester, MA
172. Waxman DJ, Jounaidi Y, Schwartz PS, Chen CS. Cytochrome P450 gene-directed enzyme prodrug therapy (GDEPT) for Cancer. (2002) Molec Therapy 5, S388.
173. Goss KA, Clodfelter K, Waxman DJ. Understanding P450 structure-function relationships using DNA shuffling mutagenesis. (2002) Boston University-Humboldt University Bioinformatics Workshop.
174. Waxman DJ. Rodent and human P450 model systems: applications in anti-cancer prodrug metabolism and cancer therapeutics. (2002) American Cancer Society Schilling Conference, Aptos, CA.

175. Jounaidi Y, Waxman DJ. Use of replication-conditional adenovirus as a helper system for enhanced delivery of prodrug-activation P450 genes for cancer therapy. (2003) American Cancer Society Schilling Conference, Aptos, CA.
176. Shipley JM, Hurst CH, Waxman DJ. Down-regulation of STAT5b transcriptional activity by ligand-activated PPAR α and PPAR γ , and activation of PPARs by environmental phthalate monoesters. (2002) Annual Superfund Meeting, Tucson, AZ.
177. Lu H, Waxman DJ. Anti-tumor activity of methoxymorpholinyl doxorubicin: potentiation by cytochrome P450 3A metabolism. (2003) 32nd Annual New England Pharmacologists Meeting
178. Hurst CH, Waxman DJ. Trans-activation of PXR by phthalate monoesters. (2003) Soc. of Toxicol. Ann. Mtg.
179. Waxman DJ, Jounaidi Y, Chen C-S, Lu H, Hurst CH, Schwartz PS. Applications of cytochrome P450 gene therapy in cancer therapeutics. (2003) British Toxicology Society Annual Congress, 44; (2004) Toxicology 194, 213.
180. Su T, Waxman DJ. Impact of dimethyl sulphoxide on expression of nuclear receptors and drug-inducible cytochromes P450 (CYFs) in primary rat hepatocytes. (2003) ASPET Annual Meeting, San Diego, CA.
181. Park S-H, Waxman DJ. Fatty acid modulation of the transcriptional activity of hepatocyte nuclear factor 4 α (HNF4 α) and STAT5b. (2003) 85th Endocrine Society Meeting, Philadelphia, PA, P2-296.
182. Park S-H, Wiwi CA, Waxman DJ. Signaling cross-talk between STAT5b and liver-enriched nuclear receptor HNF4 α . (2003) 85th Endocrine Society Meeting, Philadelphia, PA, OR3-6.
183. Landsman T, Waxman DJ. Confocal immunofluorescence analysis of liver growth hormone receptor: role of CIS and the proteasome in GHR internalization and degradation. (2003) 85th Endocrine Society Meeting, Philadelphia, PA, P3-342.
184. Waxman DJ, Jounaidi Y, Chen CS, Lu H, Su T, Schwartz PS. P450, anti-cancer drugs and gene therapies. (2003) 13th Intl Conf Cyt P450: Biochem, Biophys Drug Metab, S61.
185. Waxman DJ Ahluwalia A, Clodfelter K. Global gene expression analysis of xenochemical and hormonal responses in rat liver using high density oligonucleotide microarrays. (2003) Drug Discovery Technology Meeting, Boston, MA.
186. Clodfelter KH, Waxman DJ, Vajda S. Examining protein hot-spots using computational solvent mapping algorithms. (2003) Modeling Protein Interactions in Genomes Conf, Stony Brook, NY.
187. Clodfelter KH, Waxman DJ, Vajda S. Analysis of cytochrome P450 structure by computational solvent mapping algorithms. (2003) Intl Workshop in Bioinformatics and System Biology, Dresden, Germany.
188. Waxman DJ, Shipley JM, Hurst CH. Interaction of phthalate esters with nuclear receptors. Cross-talk with hormone-activated signaling pathways. (2003) Superfund Basic Research Program Ann Mtg, Dartmouth College, Hanover NH.
189. Clodfelter KH, Waxman DJ, Vajda S. Computational solvent mapping reveals major differences in substrate binding between bacterial and mammalian cytochrome P450s. (2004) NEDMDG Summer Symposium, Shrewsbury, MA.
190. Kaya T, Mohr S, Waxman DJ, Vajda S. Docking of phthalate monoesters to PPAR γ . (2004) NEDMDG Summer Symposium, Shrewsbury, MA.

191. Wiwi CA, Gupte M, Inoue Y, Gonzalez FJ, Waxman DJ. Sexually dimorphic P450 gene expression in liver-specific hepatocyte nuclear factor 4 α (HNF4 α)-deficient mice. (2004) 86th Endocrine Society Meeting, New Orleans, LA.
192. Laz EV, Wiwi CA, Waxman DJ. Sexually dimorphic expression of proteins in rat liver nuclear extracts: role of growth hormone. (2004) IUBMB/ASBMB Meeting, Boston, MA, C244.
193. Landsman T, Waxman DJ. Role of CIS in growth hormone receptor internalization and degradation. (2004) IUBMB/ASBMB Meeting, Boston, MA, C273.
194. Wiwi CA, Gupte M, Landsman T, Laz EV, Waxman DJ. Signal transduction pathways mediating hormonal regulation of P450s and other drug-metabolizing enzymes. (2004) Microsomes and Drug Oxidations Conference, Mainz, Germany.
195. Waxman DJ, Wiwi CA, Landsman T, Laz E, Gupta M. Mechanisms in the pulsatility of hepatic growth hormone signaling. (2004) European Society for Pediatric Endocrinology 43rd Annual Meeting, Basel, Switzerland.
196. Waxman DJ, Jounaidi Y, Chen CS, Lu H, Su T. Cytochrome P450 prodrug-based gene therapy for cancer. (2004) Pharmaceutical Education Associates PRODRUGS Conference, Philadelphia, PA.
197. Hurst CH, Waxman DJ. Interaction of environmental chemicals with the nuclear receptor PXR. (2004) 3rd PCB Workshop, Champaign-Urbana, IL.
198. Waxman DJ. Apoptosis and the application of P450 Prodrug activation gene therapy for cancer treatment. (2004) ASCO/Children's Oncology Group (COG) Sympos: Apoptosis and cell survival pathways as potential therapeutic strategies in pediatric oncology, Atlanta, GA.
199. Clodfelter KH, Waxman DJ, Vajda S. Computational solvent mapping reveals major differences in substrate binding between bacterial and mammalian cytochrome P450s. (2004) New Engl Member Enzyme Conf.
200. Clodfelter KH, Waxman, Vajda S. Analysis and comparison of bacterial and mammalian cytochrome P450 by computational solvent mapping. (2004) Zaragoza Bioinformatics Conference, Zaragoza, Spain, 65.
201. Su T and Waxman DJ. Adenoviral delivery of pan-caspase inhibitor p35 enhances P450 gene-directed enzyme prodrug therapy using cyclophosphamide. (2005) AACR Annual Meeting, Anaheim, CA.
202. Waxman DJ, Ray WJ, Holloway MG, Clodfelter KH, Hodor P, Park SH, Davey HW. Sex-dependent gene expression in mouse liver is extensive and largely dependent upon STAT5b: STAT5b-dependent activation of male genes and repression of female genes in male liver. (2005) 87th Endocrine Society Meeting, San Diego, CA.
203. Wiwi CA, Waxman DJ. Sex-dependent, growth hormone regulation of hepatocyte nuclear factor 4 α . (2005) 87th Endocrine Society Meeting, San Diego, CA.
204. Ma J, Waxman DJ. Metronomic cyclophosphamide treatment induces tumor regression and has antiangiogenic effects. (2005) 22nd Ann New England Membrane Enzyme Group Mtg, Sturbridge, MA. *Best Graduate Student Poster award.
205. Holloway MG, Laz EV, Waxman DJ. Co-regulation of GH-responsive, sexually dimorphic hepatic gene expression by STAT5b and HNF4 α . (2005) 22nd Annual Meeting of the New England Membrane Enzyme Group, Sturbridge, MA.

206. Kumar S, Sun L, Liu H, Muralidhara BK, Chen CS, Waxman DJ, Halpert JR. Directed evolution of mammalian cytochrome P450 2B1 enhanced activity and stability. (2006) Experimental Biology (FASEB) Meeting.
207. Ma J, Waxman DJ. Anti-angiogenic effects of metronomic cyclophosphamide. (2006) 35th Ann New Engl Pharmacologists Mtg, Waltham, MA.
208. Waxman DJ, Jounaidi Y, Chen C-S, Su T, Ma J. Cytochrome P450 prodrug-based gene therapy for cancer. (2006) 4th Ann Israeli Society of Gene Therapy Conference, Tel Aviv, Israel.
209. Laz EV, Chen C-S, Waxman DJ. Characterization of GH-responsive transcription factors preferentially expressed in adult female liver. (2006) 88th Endocrine Society Meeting, Boston, MA.
210. Holloway MG, Cui Y, Hennighausen L, Waxman DJ. Impact of liver-specific *Stat5a-Stat5b* deletion on sexual dimorphism of liver gene expression. (2006) 88th Endocrine Society Meeting, Boston, MA.
211. Waxman DJ, Holloway MG, Laz EV, Clodfelter KH, Wiwi CA, Peters TL. GH signaling and the regulation of sex-specific liver gene transcription. (2006) 88th Endocrine Society Meeting, Boston, MA.
212. Ma J, Waxman DJ. Tumor specific, P450-dependent metabolic activation of anti-cancer prodrugs: anti-angiogenic action of metronomic cyclophosphamide. (2006) 16th International Symposium on Microsomes and Drug Oxidations, Budapest, Hungary, 80.
213. Holloway MG, Cui Y, Hennighausen L, Waxman DJ. Loss of sexually dimorphic liver CYP gene expression upon liver-specific deletion of *Stat5a-Stat5b* locus. (2006) 16th International Symp Microsomes and Drug Oxidation Meeting, Budapest, Hungary, 239.
214. Gu J, Chen CS, Wei Y, Fang C, Xie F, Kannan K, Yang W, Waxman DJ, Ding X. A mouse model with liver-specific deletion and global suppression of the NADPH-cytochrome P450 reductase gene: characterization and utility for in vivo studies of cyclophosphamide disposition. (2006) 14th North American ISSX Meeting.
215. Waxman DJ, Chen CS, Su T, Ma J, Jounaidi Y. Cancer therapy using cytochrome P450 genes. (2006) AAPS Annual Meeting, San Antonio, Texas.
216. Bagchi G, Hurst CH, Waxman DJ. Impact of methoxyacetic acid, an endocrine disrupting chemical, on androgen receptor-mediated transcription. (2006) Superfund Basic Research Program Annual Meeting, San Diego, CA.
217. Ma J, Waxman DJ. Modulation of the anti-tumor effect of metronomic cyclophosphamide by the anti-angiogenic agent Axitinib (AG-013736). (2007) AACR Annual Meeting.
218. Chen CS, Jounaidi Y, Su T, Waxman DJ. Improved intratumoral cyclophosphamide pharmacokinetics and enhanced anti-tumor activity in a P450 2B11-based cancer gene therapy model. (2007) AACR Annual Meeting.
219. Jounaidi Y, Doloff JC, Ma J, Waxman DJ. Enhanced anti-tumor activity of weekly low dose cyclophosphamide by timed, weekly administration of the bioreductive prodrug tirapazamine. (2007) AACR Annual Meeting.
220. Doloff JC, Waxman DJ, Jounaidi Y. Adeno-hTERT-E1A, a highly oncolytic, hTERT promoter-regulated replication-conditional adenovirus. (2007) Amer Soc Gene Therapy Annual Meeting.
221. Bagchi G, Shipley JM, Hurst CH, Waxman DJ. Interactions of endocrine-active environmental chemicals with nuclear receptors. (2007) 4th Copenhagen Workshop on Endocrine Disruptors.

222. Kumar S, Sun L, Chen CS, Waxman DJ, Halpert JR. Designing mammalian cytochromes P450 for enhanced activity and stability. (2007) 15th Intl Conf. Cytochrome P450, Bled, Slovenia.
223. Waxman DJ, Laz EV, Holloway MG, Wauthier V, Miles GD, Clodfelter K, Peters TA. Transcriptional regulation of sex-specific CYPs by STAT5b and HNF4 α . (2007) 15th Intl Conf Cytochromes P450 Biochemistry, Biophysics, Functional Genomics, Bled, Slovenija.
224. Waxman DJ, MA, J; Doloff, J; Jounaidi Y; Chen, C-S. Cytochrome P450 prodrug activation gene therapy for cancer. (2007) AAPS Annual Meeting, San Diego, California.